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Referat: 
Bei der vorliegenden Arbeit handelt es sich um experimentelle Untersuchungen zu 
funktionellen Aspekten der neurovaskulären Einheit im Tiermodell. Mittels Licht,- 
Fluoreszenz- und der Elektronenmikroskopie sowie diverser immunhistochemischer 
Nachweisverfahren konnten wir verschiedene Populationen der neurovaskulären Einheit 
näher charakterisieren. So konnten wir nachweisen, dass im Hirnparenchym eine 
Population CD11c-positiver, dendritischer Zellen existiert, welche im gesunden Gehirn 
hauptsächlich an Prädilektionsstellen für Entmarkungsherde im Rahmen der Multiplen 
Sklerose vorkommt. Weiterhin zeigten wir im Tiermodell, dass die über Diphterietoxin 
vermittelte Oligodendrozytendepletion mit einer Demyelinisierung der Axone im Gehirn 
einhergeht, wobei die Freisetzung und Drainage der Antigene in zervikale Lymphknoten 
keine gegen das Gehirn gerichtete Autoimmunität auslöst. Ebenso untersuchten wir den 
Beitrag endothelialer Tight junctions zur Bluthirnschrankenstörung im Modell der fokalen 
Ischämie an der Ratte. Hierbei waren wir in der Lage nachzuweisen, dass 
entgegengesetzt zur herrschenden Lehrmeinung diese nicht verantwortlich für die 
erhöhte Gefäßpermeabilität im Rahmen des Schlaganfalls im Tiermodell zu sein scheint. 
Vielmehr konnten wir mit Hilfe der Elektronenmikroskopie einen neuen Mechanismus 
aufzeigen. Diese Ergebnisse liefern neue Erkenntnisse bezüglich der Interaktion der 
verschiedenen Populationen der neurovaskulären Einheit und können somit zur 
Entwicklung neuer Modelle verschiedener Pathologien des Zentralnervensystems 
beitragen. 
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1 Einleitung 
 
1.1 Die Bluthirnschranke 
Das Phänomen der „Bluthirnschranke“ wurde zuerst von Paul Ehrlich im Jahr 1885 
beschrieben (Ehrlich 1885). In seiner Studie untersuchte Ehrlich das Sauerstoffbedürfnis 
der einzelnen Organe indem er lebenden Tieren Farbstoffe injizierte, die je nach 
vorliegendem Redoxzustand ihre Farbe wechselten. Nach erfolgter Tötung untersuchte 
er die Organe auf Unterschiede in ihrem Färbeverhalten. Hierbei stellte er fest, dass das 
Gehirn und das Rückenmark bei Verwendung von hydrophilen Farbstoffen fast farblos 
blieben, während sich andere Organe regelhaft anfärben ließen. Diese Beobachtung 
veranlasste zahlreiche andere Wissenschaftler über Jahrzehnte hinweg nach dem 
morphologischen Korrelat dieses Phänomens zu suchen. In diesem Zusammenhang ist 
unter anderem die Arbeit von Lewandowski von Bedeutung, der bereits um 1900 den 
bemerkenswerten Schluss zog, dass die Kapillaren des Zentralnervensystems den 
Übertritt bestimmter Stoffe verhindern (Lewandowski 1900). Von dieser rein 
morphologischen Beschreibung einer Barriere für bestimmte Substanzen entwickelte 
sich das Konzept einer Bluthirnschranke zu einem funktionellen Gebilde. So beschrieb 
Edwin Ellen Goldmann 1913, dass sich nicht nur das Gehirn, sondern auch der hinter 
einer Plazenta gelegene Fetus sowie fett- oder glykogenspeichernde Zellen nicht durch 
bestimmte Vitalfarbstoffe anfärben ließen. Er nahm an, dass physiologische 
Grenzmembranen und deren Fähigkeit zu einem beachtlichen Maß an Phagozytose 
diese Gewebe von anderen abschirmen (Goldmann 1913). Bei weiteren 
Untersuchungen stellte Goldmann fest, dass nicht alle Blutgefäße des Gehirns den 
Übertritt von Farbstoffen aus dem Blut verhinderten. So beschrieb er, dass Zellen des 
Plexus choroideus, der weichen Hirnhäute und der perivaskulären Räume durch die 
Farbstoffe markiert zu sein scheinen. Diese Zellen schienen fähig zur Phagozytose und 
Migration. Die perivaskulären Räume erachtete Goldmann als Lymphräume des Gehirns 
und deren phagozytierende Zellen wurden weiterhin mehrfach beschrieben (Kristensson 
und Olsson 1973, Angelov et al. 1998, Polfliet et al. 2002, Fabriek et al. 2005). 
Insbesondere ihre potentielle Bedeutung für die Pathophysiologie der 
Neuroinflammation steht momentan im Fokus wissenschaftlicher Studien (Hickey und 
Kimura 1988, Tran et al. 1998, Greter et al. 2005, Platten und Steinman 2005).  
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Die wohl bedeutendste Arbeit zur eigentlichen Lokalisation der Bluthirnschranke ist aber 
die technisch herausragende Arbeit von Reese und Karnovsky aus dem Jahr 1967. In 
ihren elektronenmikroskopischen Studien nutzten die Autoren intravenös applizierte 
Meerrettichperoxidase als Permeabilitätsarker. Nach Konversion in ein 
elektronendichtes Präzipitat mittels einer Diaminobenzidine-Reaktion konnten Reese 
und Karnovsky belegen, dass das morphologische Korrelat der Bluthirnschranke, wie 
von Lewandowski geschlussfolgert, in der Tat das Kapillarendothel ist (Reese und 
Karnovsky 1967). Sie nahmen an, dass Verschlusskontakte zwischen benachbarten 
Endothelzellen in Form von Tight junctions den Übertritt von Stoffen aus den 
Blutgefäßen in das Hirnparenchym verhindern.  
 
Diese Form der dichten Zellkontakte besteht hauptsächlich aus dem 
Transmembranprotein Occludin, der Proteinfamilie der Claudine und 
junktionsassoziierten Proteinen (JAMs). Alle diese Komponenten werden über 
intrazelluläre Proteine aus der ZO- Familie (ZO-1, ZO-2 und ZO-3) am Aktingrundgerüst 
der Zellen verankert (Sandoval und Witt 2008, Engelhardt und Sorokin 2009). Da die 
genannten Bestandteile sich aber auch in Epithelzellverbänden und Endothelien 
peripherer Organe finden, kann die Sonderstellung der Hirngefäße nicht durch deren 
Vorhandensein erklärt werden. Gleichwohl wurden aber auch Komponenten der Tight 
junctions identifiziert, die für das Gehirn spezifisch sind. Diese sind unter anderem 
Cingulin sowie Claudin- 3 und 5 (Hawkins & Davis 2005, Liebner et al. 2000). Ob diese 
Proteine funktionell aber tatsächlich die Bluthirnschrankeneigenschaften bestimmen, ist 
derzeit nicht abschließend geklärt (Abbildung 1). 
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1.2 Der Einfluss benachbarter Zellpopulationen und das Modell der 
neurovaskulären Einheit 
Da bislang unklar war, welche Einflussfaktoren die Sonderstellung des Kapillarendothels 
zerebraler Gefäße bestimmen, wurden zahlreiche Studien unternommen, um diese 
Frage zu klären. Dabei ist es nötig, sich den komplexen Aufbau der neurovaskulären 
Einheit zu vergegenwärtigen, da sowohl der Einfluss verschiedener, benachbarter 
Zellpopulationen als auch Komponenten der extrazellulären Matrix beschrieben wurde. 
Das Modell der neurovaskulären Einheit geht dabei von drei Kompartimenten aus, die 
jeweils durch distinkte Basalmembranen klar begrenzt werden (Bechmann et al. 2007). 
Das erste Kompartiment bildet die Gefäßwand, die aus Endothelzellen, Perizyten und 
außerhalb des Kapillarbettes auch glatten Muskelzellen bestehen kann. Hier 
unterscheidet man verschiedene Schichten von Basalmembranen, welche zum einen 
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das Endothel und zum anderen Perizyten und glatte Muskelzellen umschließen. Das 
zweite Kompartiment der neurovaskulären Einheit repräsentiert der perivaskuläre 
(Virchow-Robin) Raum, welcher sich zwischen der äußeren vaskulären Basalmembran 
und der astrozytären Basalmembran der Membrana limitans gliae perivascularis (Glia 
limitans) befindet. Hier lassen sich leptomeningeale Mesothelzellen und perivaskuläre 
Makrophagen identifizieren. Letztere werden in der Literatur fälschlicherweise häufig mit 
Perizyten gleichgesetzt, welche per Definition jedoch zur Gefäßwand, das heißt dem 
ersten Kompartiment gehören (Krueger und Bechmann 2010). Das dritte Kompartiment 
bildet das eigentliche Hirnparenchym, welches Astrozyten, Oligodendroglia, Microglia 
und Neurone enthält (Abbildung 2). Alle diese Zellpopulationen und Basalmembranen 
tragen als funktionelle Einheit zur Aufrechterhaltung der Bluthirnschranke und somit zur 
Aufrechterhaltung der Homöostase innerhalb des ZNS bei (Weiss et al. 2009). 
 
1.2.1 Endothelzellen 
Als erste Barriere morphologische Barriere zwischen dem Blut und dem Gehirn wurde 
das Endothel über Jahrzehnte hinweg allein für die Ausbildung der Bluthirnschranke 
verantwortlich gemacht (Abbildung 3). Neben den beschriebenen Tight junctions tragen 
Endothelzellen jedoch auch in metabolischer Hinsicht zur beobachteten Barrierefunktion 
bei (Sandoval und Witt 2008). So ist ein erhöhter Mitochondriengehalt gegenüber 
peripheren Gefäßen Ausdruck einer Vielzahl energieabhängiger Prozesse zur 
Aufrechterhaltung der Homöostase und zum Abbau schädlicher oder therapeutische 
eingesetzter Substanzen (Oldendorf et al. 1977, Witt et al. 2001). Dabei unterliegen 
Endothelzellen einer Vielzahl an Einflussfaktoren benachbarter Zellpopulationen, welche 
die Gefäßpermeabilität innerhalb des Gehirns in typischerweise herabsetzen (Weiss et 
al. 2009) 
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1.2.2 Astrozyten 
Ursprünglich wurden aber Astrozyten für die Ausbildung der 
Bluthirnschankeneigenschaften innerhalb der Endothelschicht verantwortlich gemacht 
(Stewart et al. 1981, Janzer und Raff 1987; Arthur et al. 1987). So konnte in diversen 
Modellen gezeigt werden, dass Endothelien unter dem Einfluss von Astrozyten eine 
verringerte Permeabilität gegenüber gelösten Farbstoffen sowie einen erhöhten 
transendothelilalen Widerstand aufwiesen. Verschiedene von ihnen produzierte 
Faktoren wie TGF-β und Ang-1 wirken während der Angiogenese und im Alter 
stabilisierend auf den Zusammenhalt benachbarter Endothelzellen und unterstützen die 
Ausbildung typischer Tight junctions (Abbott et al 2006). Durch ihre weit verzweigten 
Ausläufer stehen Astrozyten sowohl mit Synapsen als auch mit Blutgefäßen in Kontakt 
(Koehler et al. 2006). Diese Eigenschaft kennzeichnet ihre Fähigkeit zur Vermittlung der 
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sogenannten neurovaskulären Kopplung, durch welche neuronale Impulse an arterielle 
Blutgefäße vermittelt werden. Daher beteiligen sich Astrozyten an der Regulation des 
zerebralen Blutflusses (Koehler et al. 2006). Weiterhin regulieren Astrozyten die 
Wasseraufnahme des Gehirns über Aquaporine, welche ebenfalls für die Ausbildung 
von Ödemen beim Schlaganfall von Bedeutung sind (Kleffner et al. 2008). 
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1.2.3 Perizyten 
Perizyten sind neben den glatten Muskelzellen eine eigenständige Zellpopulation der 
Gefäßwand (Krueger und Bechmann 2010). Die Gefäße des Zentralnervensystems 
zeichnen sich gegenüber peripheren Gefäßen durch ein gehäuftes Auftreten dieser 
Zellen aus (Shepro und Morel 1993). Durch Invaginationen, welche als „peg-socket 
contacts“ bezeichnet werden, kommunizieren Perizyten direkt mit Endothelzellen 
Armulik et al. 2005). Dieser enge Kontakt ist möglich, da im Bereich der Kapillaren beide 
Populationen allein durch eine Basalmembran voneinander getrennt sind. Doch nicht 
nur morphologisch, auch funktionell sind Perizyten mit dem Endothel eng verbunden. Im 
Rahmen der Angiogenese stabilisieren Perizyten die Endothelzellschläuche und 
induzieren in ihnen die typischen Bluthirnschrankeneigenschaften (Lindahl et al. 1997) 
wobei Endothelzellen Periyzten im Rahmen dieser Prozesse rekrutieren (Daneman et al. 
2010). Kürzlich konnte ebenfalls gezeigt werden, dass Perizyten durch ihre Fähigkeit zur 
Kapillarkontraktion an der Regulierung des zerebralen Blutflusses beteiligt sein könnten 
(Peppiatt et al. 2006, Fernandez-Klett et al. 2010). Darüber hinaus zeigen Studien, dass 
diese Population als wichtiges, regulierendes Element der neurovaskulären Einheit im 
Rahmen von zahlreichen Pathologien des Zentralnervensystems eine entscheidende 
Rolle spielt (Winkler et al 2011). 
 
1.2.4 Microglia 
Microglia wurden erstmals 1932 von del Rio-Hortega als eigenständige Popultion unter 
den Gliazellen beschrieben. Im gesunden Zentralnervensystem besitzen „ruhende“ 
Microgliazellen kleine Zellkörper und lange, verzweigte Fortsätze während aktivierte 
Microglia nur noch kurze Fortsätze zeigen und eine amöboide Form annehmen. Mit 
diesem Zustandswechsel verändern Microgliazellen ebenfalls die Expression von 
Proteinen an ihrer Oberfläche und schütten eine Vielzahl von Chemokinen aus. In der 
Literatur wird ebenfalls eine Subpopulation im perivaskulären Raum unterschieden, 
welche einem Austausch mit Leukozyten aus dem Blut unterliegt (Hickey und Kimura 
1988). Dies trifft jedoch nicht für Mikroglia im eigentlichen Neuopil zu (Mildner et al. 
2007), weshalb die von Hickey und Kimura beschriebene Population treffender als 
perivaskuläre Makrophagen bezeichnet werden sollte. Als phagozytierende Zellen 
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könnten diese aus immunologischer Sicht ebenfalls an der Bildung der Bluthirnschranke 
beteiligt sein, wie es bereits Goldmann 1913 vermutete (Goldmann 1913). 
 
1.2.5 Neurone 
Bis heute ist die genaue Beteiligung der Neurone an der Regulation der 
neurovaskulären Einheit weitgehend unverstanden, doch in Betracht des hohen 
Energiebedarfs und der direkten Korrelation zwischen neuronaler Aktivität und dem 
Blutfluss, liegt eine enge Kopplung nahe (Sandoval und Witt 2008). Ursprünglich wurden 
für die Kommunikation mit den Blutgefäßen allerdings Astrozyten als Mediatoren 
verantwortlich gemacht (Koehler et al. 2006). Doch auch ein direkter Einfluss von 
Nervenzellen auf die Funktion der neurovaskulären Einheit und insbesondere des 
Endothels wurde diskutiert (Cohen et al. 1996, 1997, Hamel 2006). Nicht zuletzt gewinnt 
das Konzept der neurovaskulären Einheit im Rahmen des ischämischen Schlaganfalls 
aufgrund der Beteiligung der Gesamtheit der Zellpopulationen innerhalb der 
neurovaskulären Einheit immer mehr an Bedeutung (Endres et al. 2008, Sandoval und 
Witt 2008). Bei der beachtlichen Anzahl von über 1000 verschiedenen, theoretischen 
Therapieansätzen (O’Collins et al. 2006) ist die Übertragbarkeit von Studienergebnissen 
aus vielfach unphysiologischen Modellen durchaus kritisch zu hinterfragen, da in ihnen 
häufig nur Effekte auf einzelne Populationen unter Vernachlässigung des gesamten 
neuronalen Milieus untersucht werden. Dies wiederum ist für die Entwicklung effektiver 
neuroprotektiver Therapien von entscheidender Bedeutung (Endres et al. 2008). 
 
1.3 Übernahme der Metapher einer Bluthirnschranke in den Kontext der 
Neuroimmunologie 
Der Begriff der Bluthirnschranke wurde in der Vergangenheit irreführenderweise häufig 
mit dem Begriff des Immunprivilegs in Verbindung gebracht. Dieser wiederum geht aus 
frühen Transplantationsexperimenten des 19. Jahrhunderts hervor, bei denen gezeigt 
werden konnte, dass körperfremdes Gewebe nur einer abgeschwächten Immunantwort 
unterliegt, sofern es in das Gehirn oder die vordere Augenkammer transplantiert wird. 
Peter Medawar griff diese Experimente auf und konnte zeigen, dass eine 
Abstoßungsreaktion aber eingeleitet werden konnte, sofern ein weiteres Transplantat 
unter die Haut der Versuchstiere gebracht wurde. Er schlussfolgerte nun, dass Antigene 
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im Gehirn ebenfalls zwar einer Immunantwort unterliegen, aber keine Immunreaktion 
hervorrufen können (Medawar 1948). Er begründete dies mit der Abwesenheit eines 
Lymphabflusses aus dem Gehirn, obwohl bereits frühe, in deutscher Sprache verfasste 
Arbeiten diesen über die Lamina cribrosa in die nasale Schleimhaut postulierten 
(Schwalbe 1869). Diese Sichtweise fand später erneut große Beachtung (Cserr und 
Knopf 1992, Koh et al. 2005). Die kausale Verknüpfung beider Konzepte, die erfolgte 
durch Barker und Billingham, welche die endotheliale als auch die astrogliale, 
morphologische Barriere mit der eingeschränkten Lymphozytenrekrutierung in das 
Gehirn in Verbindung brachten (Barker und Billingham 1977). Dies führte jedoch 
nachhaltig zu der vereinfachten Sichtweise, dass die Bluthirnschranke das 
Immunprivileg bedingt. 
Die Rekrutierung von Leukozyten aus dem Blut in das Gehirn hat aus 
pathophysiologischer Sicht im Rahmen der Neuroinflammation eine enorme Bedeutung 
(Engelhardt und Ransohoff 2005). Das Verständnis ihrer Regulation und Einflussnahme 
auf Autoimmunerkrankungen wie der Multiplen Sklerose ist für die Entwicklung 
geeigneter Therapieansätze und deren Überführung in den klinischen Alltag 
unerlässlich. Jedoch neigen viele Studien zu diesem Thema zu einer vereinfachten 
Darstellung der komplexen anatomischen Verhältnisse im Bereich der neurovaskulären 
Einheit, was dazu führt, dass Kommentare wie „Leukozyten überwinden die 
Bluthirnschranke“ außer Acht lassen, ob sich diese Zellen im Rahmen von 
Entzündungsprozessen tatsächlich in das Gehirn, oder nur in den angrenzenden 
perivaskulären Raum rekrutieren (Bechmann et al 2007). Diese Unterscheidung 
wiederum ist von großem klinischem Interesse, wie im Tiermodell erfolgreich gezeigt 
werden konnte (Tran et al. 1998, Toft-Hansen et al. 2007). Weiterhin verleitet die 
Übernahme des Begriffes der Bluthirnschranke in den immunologischen Kontext zu der 
Annahme, dass die Rekrutierung von Leukozyten in das Zentralnervensystem den 
gleichen Mechanismen folgt, wie der Eintritt im Blut gelöster Substanzen in das Gehirn. 
Während sich die Beobachtungen der Bluthirnschranke für hydrophile Substanzen auf 
das Kapillarbett beschränken, findet die Rekrutierung von Immunzellen im Rahmen von 
Entzündungen hingegen eher in postkapillären Venulen statt (Raine et al. 1990, 
Bechmann et al. 2007). Diese Sicht wird durch den Befund gestützt, dass die 
Überwindung der Bluthirnschranke durch Leukozyten nicht mit einer herabgesetzten 
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Barriefunktion für hydrophile Stoffe einhergeht (Perry et al. 1997, Bechmann et al. 
2005). Darüber hinaus zeigen Studien, dass die Überwindung des Endothels durch 
Leukozyten nicht mit einer Öffnung der Tight junctions einhergeht, sondern als 
Diapedese durch die Endothelzellen hindurch erfolgt (Wolburg et al. 2005). Dass die 
Endothelschicht der Gefäße als Barriere im Rahmen der Infiltration von Zellen keine 
bedeutende Rolle spielt, konnte im Tierversuch auch in Abwesenheit von Pathologien 
gezeigt werden, wobei durch die Verwendung von Knochenmarkschimären Artefakte 
durch die Bestrahlung diskutiert werden können (Bechmann et al.2001, Priller et al. 
2001, Mildner et al 2007). Im Kontext der Leukozyteninvasion in das 
Zentralnervensystem ist daher die Aussage von Barker und Billingham bemerkenswert, 
die annahmen, dass auch das Gehirn selbst Stoffe beinhalten kann, die das Eindringen 
von Lymphozyten aus dem Blut verhindern können (Barker and Billingham 1977). Unter 
Berücksichtigung der topographischen Verhältnisse zerebraler Gefäße außerhalb des 
Kapillarsegmentes diskutiert man heute einen zweiphasigen Verlauf der 
Neuroinflammation (Bechmann et al. 2007). Nach der Überwindung der Gefäßwand 
befinden sich Leukozyten auf ihrer Passage ins Gehirn demnach zunächst im 
perivaskulären Raum und müssten weiterhin die Membrana limitans gliae perivascularis 
als auch deren Basalmembran überwinden. Dass Leukozyten aus dem Blut nicht 
zwangsläufig diese letzte Barriere überwinden können, zeigen eindrucksvoll die 
Experimente von Tran und Kollegen (Tran et al 1998), in denen die Depletierung 
perivaskulärer Makrophagen das Eindringen von inflammatorischen Zellen in das 
Neuropil im Rahmen des Tiermodells der Multiplen Sklerose verhindern konnte. Doch 
neben den perivaskulären Makrophagen scheinen auch andere Regulationssysteme die 
Infiltration von Zellen in das Zentralnervensystem zu beeinflussen. So synthetisieren 
Astrozyten der Glia limitans konstitutiv den sogenannten Todesliganden CD95L, welcher 
den Übertritt von Zellen aus dem perivaskulären Raum in das Neuropil beeinflusst 
(Bechmann et al. 1999). Darüber hinaus unterscheidet sich der molekulare Aufbau der 
Basalmembranen der Gefäßwand von der astrozytären Basalmembran (Sixt et al. 
2001). Somit sind Zellen, welche die Gefäßwand überwinden können enzymatisch nicht 
zwangsläufig fähig, die Glia limitans zu überwinden (Agrawal et al. 2006). In diesem 
Zusammenhang wird der Population der perivaskulären Markophagen eine 
entscheidende Rolle zuerkannt, indem diese durch die Expression von 
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Matrixmetalloproteinasen entscheidend an der Überwindung der astrozytären 
Basalmembran beteiligt zu sein scheinen (Toft-Hansen et al. 2006). Desweiteren wurde 
diskutiert, ob sich unter diesen Zellen eine Subpopulation CD11c- positiver, 
antigenpräsentierender Zellen befindet, welche im Sinne einer Restimulierung 
rekrutierter Lymphozyten zur Infiltration des Neuropils oder des Transportes spezifischer 
Antigene aus dem Gehirn in periphere Lymphknoten beiträgt (Greter et al. 2005). 
 
1.4 Die Bluthirnschrankenstörung beim ischämisch induzierten Schlaganfall 
Der ischämisch induzierte Schlaganfall repräsentiert heute eine der häufigsten 
Todesursachen weltweit (Donnan et al. 2009). Hierbei führt eine Verringerung des 
zerebralen Blutflusses zu einem intrazellulären Defizit an ATP, wodurch eine Vielzahl 
von energieabhängigen Stoffwechselvorgängen zur Aufrechterhaltung des neuronalen 
Milieus zum Erliegen kommen. Dies führt zur Schädigung von Mitochondrien, der 
Freisetzung toxischer Sauerstoffradikale und schließlich zur Entstehung eines 
intrazellulären Ödems (Dirnagl et al. 1999, Endres et al. 2009). Darüber hinaus führt die 
vermehrte Bereitstellung von VEGF (Yang et al. 2007) und der Matrixmetalloproteinasen 
MMP-2 und MMP-9 (Bauer et al. 2010) zu einer vermehrten Durchlässigkeit der 
Gefäßwände gegenüber gelösten Stoffen und erhöht die Wahrscheinlichkeit von 
Hirnblutungen, welche die Mortalität drastisch erhöhen (Sandoval und Witt 2008). Der 
eigentliche Vorgang der Bluthirnschrankenöffnung im Sinne eines Leckschlagens der 
zerebralen Gefäße wurde bislang stets mit einer Öffnung der Tight junctions 
gleichgesetzt (Mark und Davis 2002, Sandoval und Witt 2008, Weiss et al. 2009, Yang 
und Rosenberg 2011). In der Tat findet sich eine Vielzahl an Studien, die 
Veränderungen wichtiger Tight junction- assoziierter Proteine im Rahmen von 
verschiedenen Hypoxie- und Schlaganfallsmodellen beschreiben (McCaffrey et al. 2009, 
Jiao et al. 2011, Liu et al. 2012, Yu et al 2012). Der Abbau oder die Umverteilung dieser 
Proteine geschieht in dieser Phase über einen MMP-9 vermittelten Prozess der 
ebenfalls die Signalkaskade von VEGF umfasst (Bauer et al. 2010). Diese Daten 
werden durch Beobachtungen gestützt, bei denen immunhistochemische Färbungen 
von kultivierten Endothelzellschichten ein Aufbrechen der gürtelförmigen 
Schlussleistenkomplexe unter Hypoxiebedingungen zeigen sollen (Fischer et al 2000, 
Mark und Davis 2002). Leider fehlt bislang allerdings ein glaubhafter 
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elektronenmikroskopischer Nachweis dieser Öffnung. Bei genauer Betrachtung 
elektronenmikroskopischer Abbildungen, die vermeintliche Öffnungen interendothelialer 
Verschlusskontakte zeigen, erscheinen diese, falls überhaupt nachweisbar, eher fraglich 
(Matsuzaki et al. 2010, Jiao et al 2011)  
Kritisch wird zunehmend ebenfalls die Verwendung unphysiologischer Modelle der in-
vitro-, fokalen,- oder globalen Ischämie diskutiert, deren Daten in den meisten Fällen 
nicht auf die humane Pathophysiologie übertragbar sind (O’Collins et al 2006). In diesen 
Studien reichen die Methoden zur Verringerung des zerebralen Blutflusses über die 
Elektrokoagulation bis hin zum Verschluss zerebraler Gefäße durch eingeführtes 
Nahtmaterial, die in keiner Weise die humane Genese widerspiegeln. Außerdem 
erschwert die Applikation von unphysiologischen Markersubstanzen zur Überprüfung 
der Extravasation in entsprechenden Gefäßterritorien die Interpretation der Daten, da 
diesen Substanzen wie im Falle des weit verbreiteten Evans Blue auch intrinsische, 
toxische Effekte auf das Gefäßendothel nachgesagt werden (Young et al. 2007). 
 
2 Fragestellung 
Aus diesen Erkenntnissen ergaben sich für uns folgende Fragestellungen: 
1. Gibt es im Bereich der neurovaskulären Einheit eine Population an CD11c-
positiven antigenpräsentierenden Zellen und in welchem Kompartiment sind 
diese Zellen lokalisiert? 
2. Findet ein Antigentransport aus dem Gehirn in zervikale Lymphknoten im 
Rahmen des experimentell hervorgerufenen Myelinscheidenuntergangs als 
Teil einer Immunantwort statt? 
3. Ist der Verlust der Bluthirnschrankeneigenschaften des zerebralen Endothels 
mit einem Untergang endothelialer Tight junctions assoziiert? 
Diese Fragen wurden mithilfe von transgenen Mausmodellen und im Rahmen des 
experimentell induzierten Schlaganfalls an der Ratte untersucht. Dabei verwendeten wir 
hauptsächlich immunhistochemische Verfahren zur Markierung verschiedener 
Zellpopulationen und Antigene im Bereich der neurovaskulären Einheit als auch 
ultrastrukturelle Analysen mittels der Elektronenmikroskopie. 
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ABSTRACT
Rouget, in 1873, was the first to describe a population of
cells surrounding capillaries, which he regarded as con-
tractile elements. Fifty years later, Zimmermann termed
these cells ‘‘pericytes’’ and distinguished three subtypes
along the vascular tree. Since then, the discussion concern-
ing the contractile ability of pericytes has never ceased.
Current concepts of pericyte biology rather suggest critical
roles in the maintenance of homeostasis, blood–brain bar-
rier (BBB) integrity, angiogenesis, and neovascularization.
In addition, data from models of brain pathology suggest
that novel pericytes are recruited from the bone marrow,
but their respective precursor remains enigmatic. Recent
data also suggest an important role in the regulation of cer-
ebral blood flow, thus confirming Rouget’s original idea.
However, comparison of data from different studies is often
constrained by the fact that pericytes were questionably
identified. Although a clear-cut definition exists, defining
pericytes as part of the vascular wall being enclosed in its
basement membrane, pericytes are often mixed up with ad-
jacent cell types of the vascular wall, the perivascular
space, and the juxtavascular parenchyma. In fact, their
identification is difficult—if not impossible—in standard
histological sections. An unambiguous distinction, however,
is possible at the ultrastructural level and in semi-thin sec-
tions, where their location within the vascular basement
membrane can be displayed. Using these techniques in
combination with immunological staining methods allows
demarking their unique morphology and location. Here, we
review original papers describing pericytes, briefly outline
their topography within the vascular compartments,
describe methods for their identification, and summarize
current concepts of their function. VC 2009 Wiley-Liss, Inc.
INTRODUCTION
Rouget, in 1873, was the first to describe a population
of cells on capillary walls and distinguished them from
migratory leucocytes (Rouget, 1873, 1874, 1879). Fifty
years later Zimmermann renamed these Rouget cells
and termed them ‘‘pericytes,’’ as the name best describes
their location around capillary vessels. Furthermore, he
distinguished three subtypes of pericytes along the vas-
cular tree, including transitional forms to smooth muscle
cells of the tunica media. Since then, the discussion con-
cerning putative pericyte functions has never ceased.
Indeed, this issue is difficult to address as specific
markers enabling their clear-cut identification are lack-
ing. Nevertheless, there are data demonstrating peri-
cytes as taking part in several vascular signaling path-
ways, thus suggesting critical roles in the maintenance
of homeostasis, blood–brain barrier (BBB) integrity,
angiogenesis, and neovascularization (for review see
Fisher, 2009). Recent studies suggest that pericytes of
the central nervous system (CNS) are bone marrow
derived, although a respective precursor still remains
enigmatic. Moreover, there is data obtained from cell
culture experiments demonstrating that pericytes may
serve as multipotential stem cells in the adult brain
(Dore-Duffy, 2008; Dore-Duffy et al., 2006). Neverthe-
less, this potential still needs to be demonstrated
in vivo.
Much of the numerous data relating to pericytes
derives from the simple fact that they are improperly
identified and often mixed up with adjacent cell types
such as vascular muscle cells, perivascular cells, and
juxtavascular microglia. This is mainly due to the com-
plex anatomy of the neurovascular unit where three dif-
ferent compartments must be distinguished. The first
compartment is the vascular wall consisting of endothe-
lial cells forming the tunica intima, smooth muscle cells
of the tunica media, and pericytes. The second is the
neighboring perivascular (Virchow-Robin) space which
harbors leptomeningeal cells, macrophages, and other
antigen-presenting cells (Bechmann et al., 2007; Greter
et al., 2005). The third compartment is the juxtavascular
parenchyma (neuropil), which is bordered by the glia
limitans consisting of astrocytic endfeet and juxtavascu-
lar microglia (see Fig. 1). All these compartments are
delineated by distinct basement membranes (Bechmann
et al., 2001a,b; Sixt et al., 2001), providing precise mor-
phological borders for their identification.
The processes of pericytes, in contrast to smooth mus-
cle cells of the tunica media, are oriented along the axis
of the blood vessel, while smaller circumferential arms
engirdle the vascular wall (Rhodin, 1968; Rucker et al.,
2000; Zimmermann, 1923; Fig. 2A,B). At the ultrastruc-
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tural level it becomes evident that pericytes are com-
pletely covered by the vascular basement membrane
(see Fig. 3) and therefore, pericytes apparently belong to
the vascular wall (1st compartment). In fact, this condi-
tion provides the only clear-cut definition for pericytes,
because there is no selective marker for these cells (see
following text).
Both endothelial cells and pericytes contribute to the
synthesis of the vascular basement membrane (Cohen
et al., 1980; Mandarino et al., 1993). In smaller vessels,
the outer vascular membrane fuses with the membrane of
the glia limitans (‘‘fused gliovascular membrane’’),
thereby occluding the perivascular (Virchow-Robin) space
rendering a proper localization of cells within the three
Fig. 1. Topography of the neurovascular unit. (A) The scheme gives
an overview of the neurovascular interface showing a subarachnoid
vein, a postcapillary venule, and a capillary. The vascular wall is
formed by endothelial cells, pericytes, and in larger vessels additionally
smooth muscle cells of the tunica media. By definition, pericytes are
part of the vascular wall (first compartment) and are therefore morpho-
logically separated from cells of the perivascular (Virchow/Robin) space
or the juxtavascular parenchyma. This distinction is only possible at
the ultrastructural level or in semi-thin sections where the different
compartments are visible. (B) These schemes represent cross sections
through capillaries and larger vessels. The basement membranes (in
red) provide clear-cut morphological borders to distinguish the different
compartments. The inner basement membrane surrounds the endothe-
lium while the outer one surrounds the vascular wall including peri-
cytes or smooth muscle cells. In capillary vessels, the basement mem-
brane of the glia limitans fuses with the outer vascular basement
membrane, thus occluding the perivascular space.
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compartments difficult (Figs. 1 and 2). In fact, in standard
histological sections for light microscopy it is virtually
impossible to distinguish pericytes from cells of the adja-
cent compartments such as perivascular cells or juxtavas-
cular microglia. Even if the perivascular space is visible,
cells therein are often incorrectly referred to as pericytes
making interpretation and comparison of data from differ-
ent studies rather difficult (Bechmann et al., 2007).
By definition, capillaries in contrast to pre- and post-
capillary vessels lack a tunica media. Therefore, peri-
cytes and endothelial cells of capillaries are separated
by a single basement membrane with no muscle cells in-
between (Sims, 1986) allowing direct signaling through
cellular junctions (Cuevas et al., 1984), while in non-cap-
illary vessels, several layers of muscle cells exclude such
direct interaction. This is in line with the heterogeneous
density and morphology of pericytes differing from spe-
cies to species, in various organs and along the vascular
tree. These findings suggest diverse functions depending
on their position along the vascular tree and the organ
they are situated in. The varying density has been
attributed to differing hydrostatic pressure in the vascu-
lature (Sims, 2000), but may also be a consequence of
other features such as the distance to the endothelium
and/or the glia limitans. Vice versa, the density of peri-
cytes may have an impact on endothelial tightness and
thus, influence its barrier function (Sims, 1986).
IMMUNE PHENOTYPE AND ORIGIN
Identification of Pericytes
A clear-cut detection of pericytes in standard sections
for light and fluorescence microscopy is often impossible
because their cytoplasmic extensions and basement
membranes are invisible and pericytic nuclei do not
Fig. 2. Morphology of pericytes. (A) Three-dimensional reconstruc-
tion of confocal images of pericytes stained with anti-pAPN. Note the
considerable morphological heterogeneity. In longitudinal direction
their size well extends 100 lm. (B) pAPN-positive pericytes in conven-
tional fluorescence microscopy. Note that their size seems to differ
depending on whether they are located at capillaries or larger vessels.
Scale bar: 40 lm. (C) Pericytes (red; pAPN) in relation to perivascular
macrophages (green; GFP) and the astrocytic endfeet of the glia limi-
tans (blue; GFAP). Note that it in such histological sections it is impos-
sible to discern the vascular wall from the perivascular space. There-
fore, the cells located within perivascular spaces are often misconceived
as ‘‘pericytes.’’
Fig. 3. Topography of pericytes and the perivascular space. (A) Peri-
cytes are defined by their position within the outer vascular basement
membrane (dashed line). The inner vascular basement membrane sur-
rounds the endothelium (dotted line). Note that the basement mem-
brane of this capillary has fused with the membrane of the glia limi-
tans (original magnification: 70003). (B) In non-capillary vessels, the
situation is strikingly different: instead of a fused gliovascular mem-
brane, the outer vascular membrane (dashed line) and the glial mem-
brane (dashed-dotted line) border the perivascular (Virchow/Robin)
space (asterisk). The inner vascular membrane (dotted line) separates
the endothelium from the tunica media (original magnification: 30003).
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necessarily differ from those of adjacent cell types.
Semi-thin sections provide an alternative allowing easy
identification of pericytes by means of their localization
as the distinct basement membranes are demarked. This
method, although applicable, is rarely combined with
immunocytochemistry. However, pericytes do express
surface antigens allowing their identification. These are
pAPN/CD13 (Dermietzel and Krause, 1991; Kunz et al.,
1994), PDGFR-b (Lindahl et al., 1997), a-smooth muscle
actin (Nehls and Drenckhahn, 1991), desmin (Nehls
et al., 1992), NG-2 (Ozerdem et al., 2001; Ruiter et al.,
1993), the promoter trap transgene XlacZ4 (Tidhar
et al., 2001), and the regulator of G-protein signaling-5
(RGS5) (Bondjers et al., 2003; Cho et al., 2003). Unfortu-
nately, these molecules are also expressed on neighbor-
ing cell types and may be induced in adjacent cells by
experimental manipulations or under cell culture condi-
tions. Moreover, pericytes of capillaries differ from those
of larger vessels in their expression of contractile ele-
ments. If present, their use for identification is inflicted
by simultaneous expression in smooth muscle cells.
Dermietzel’s group found an ectoenzyme termed peri-
cytic aminopeptidase N (pAPN) to be an antigen suitable
for pericyte detection and proved its specificity at the ul-
trastructural level (Kunz et al., 1994). This aminopepti-
dase appears at day E18 of brain angiogenesis (Der-
mietzel et al., 1991) and belongs to the family of matrix
metalloproteinases. These are involved in zinc depend-
ent cleavage of extracellular matrix molecules as well as
non-matrix substrates such as growth factors or neuro-
peptides (Sato, 2004). It has also been observed that
regions devoid of a tight endothelium lack pAPN expres-
sion (Kunz et al., 1994). In addition, in experimental
autoimmune encephalomyelitis (EAE), a model of auto-
immune neuroinflammation, diminished pAPN expres-
sion correlated with increased permeability of the BBB
(Kunz et al., 1995). Furthermore, during neuroinflam-
mation invasive pAPN positive cells, which were not
associated with vessels, could be observed within the
white matter of the spinal cord. These cells were also
positive for ED-1 and OX-17 which is strongly upregu-
lated on activated rat macrophages and microglia during
EAE (Hickey et al., 1985). This raises the intriguing
question whether subtypes of pericytes transform into
such pAPN-positive macrophages and infiltrate the neu-
ropil or whether microglial cells are induced to express
this pericyte marker. An alternate explanation would be
that there is a blood-borne precursor positive for both,
pericyte and macrophage markers, which infiltrates the
neuropil under pathologic conditions. In fact, there is
data suggesting that at least some pericytes derive from
the monocyte lineage (see following text), but only
recent approaches of cell targeted transgenic expression
of fluorescent proteins will allow resolving this issue.
Members of the Monocyte/Macrophage Family?
Pericytes were repeatedly reported to express markers
of the monocyte/macrophage lineage such as ED1 or
CD11b in the rat (Balabanov et al., 1996; Graeber et al.,
1989). This was supported by in vitro studies showing
that they respond to IFN-g stimulation with up-regula-
tion of the major histocompatibility class II antigen
(MHC-II) (Dore-Duffy and Balabanov, 1998). Using anti-
body-coated zymosan and fluorochrome-conjugated poly-
styrene beads, Balabanov also demonstrated their phag-
ocytic potential (Balabanov et al., 1996). However, as
clear-cut identification is lacking in these studies, it is
possible that the reported observations relate to perivas-
cular macrophages which may also be part of pericyte
cultures. In fact, perivascular macrophages exhibit vivid
phagocytosis, act as antigen-presenting cells and are
supplemented by hematogenous cells (Bechmann et al.,
2001a,b; Greter et al., 2005; Hickey and Kimura, 1988;
Priller et al., 2001). The latter has also been suggested
for pericytes by using animal models of stroke and cor-
neal vasculogenesis (Kokovay et al., 2006; Ozerdem
et al., 2005), but these studies lacked electron micros-
copy or semi-thin analysis for unequivocal identification.
Therefore, finding a pericyte precursor or lineage is still
subject of further investigation, and the question of
whether pericytes represent a specialized subtype or
immature form of macrophages which can under certain
conditions be recruited to the neuropil is not yet
answered.
CURRENT CONCEPTS OF PERICYTE
FUNCTIONS
Regulation of BBB Function
Since the discovery by Rouget in 1873, several con-
cepts of pericyte functions have been repeatedly dis-
cussed. Due to the higher density of pericytes in the
CNS compared with peripheral vessels, a critical role in
the maintenance of BBB characteristics in endothelial
cells has been assumed. Conversely, this function has
been attributed to astrocytes (Arthur et al., 1987; Janzer
and Raff, 1987, Stewart and Wiley, 1981), but there is
also data showing the development of endothelial tight
junctions independent from astrocytes (Felts and Smith,
1996; Jaeger and Blight, 1997). In mice lacking glial
acidic fibrillary protein (GFAP) on astrocytes, it was
noted that the CNS microvasculature displayed
increased pericyte coverage (Balabanov et al., 1998),
which was interpreted as a possible counter-regulation
for vascular leakage. This hypothesis could later be
experimentally affirmed. Addition of pericytes to co-cul-
tured monolayers of endothelial cells effected increased
barrier function for hydrophilic molecules and, in addi-
tion, enhanced transendothelial resistance (Dente et al.,
2001). It is important to note that this does not exclude
the critical role of astrocytes in these processes but
rather suggests a dialogue between several populations
of the neurovascular unit and the possible existence of
compensatory mechanisms which may take over each
other’s role in case of impaired function.
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Impact on Vascular Development
A necessity to bring forth such BBB properties is, of
course, a proper vascular development and its mainte-
nance. This is cardinally driven by the recruitment/differ-
entiation of pericytes to sites of angiogenesis or neovascu-
larization which involves the platelet derived growth fac-
tor-b (PDGF-b) and the corresponding receptor PDGFR-b
(for review see Gerhardt and Betsholtz, 2003). This
receptor is expressed on pericytes while its ligand is pro-
duced by sprouting endothelial cells (Hellstrom et al.,
1999; Lindahl et al., 1997). Co-culture studies demon-
strate that PDGF-b acts as a mitogen and chemoattrac-
tant cue for mural precursors (Hirshi et al., 1998, 1999).
Mice lacking PDGF-b or its receptor develop identical
vascular phenotypes exhibiting pericyte-depleted vessels
leading to neonatal lethality, microvascular leakage, and
hemorrhage (Leveen et al., 1994; Soriano, 1994).
This has been further investigated using the same
model in combination with the two angiopoietins, Ang-1
and Ang-2, and their receptor Tie-2. The latter is
expressed on endothelial cells, whereas perivascular
cells and pericytes are responsible for the production of
Ang-1 (Davis et al., 1996; Suri et al., 1996). It was noted
that in PDGF-b (deficient mice Ang-1 readily restored
the vascular structure and function (Uemura et al.,
2002). Therefore, the binding of Ang-1 to the receptor
Tie-2 fostered vascular stabilization. Conversely, and
contrary to Ang-1, Ang-2 is merely a destabilizing factor
which is restricted to endothelial cells in areas of vascu-
lar remodeling and binds to Tie-2 without inducing the
expected signal transduction (Maisonpierre et al., 1997).
This has been confirmed by several other studies all sug-
gesting an antagonistic model of these two ligands (Mai-
sonpierre et al., 1997; Sato et al., 1995; Suri et al.,
1996). The reduction of BBB leakage via Ang-1 has also
been shown in ischemic models (Zhang et al., 2002) in
which hypoxia induces Ang-2 without changing the
expression patterns of Ang-1 (Mandriota and Pepper,
1998). Therefore, Ang-2 apparently has a pro-angiogenic
effect, whereas Ang-1 and its source, the pericytes, act
in a stabilizing way. Consequently, the current concept
is that the developing vasculature remains unstable and
immature until pericytes or its precursors are recruited
(Benjamin et al., 1998).
Once pericytes are in position, vascular stability is
sustained by sphingosine-1-phosphate (S1P) signaling
which involves the molecules N-cadherin and VE-cad-
herin (Armulik et al., 2005). After binding of S1P to its
endothelial receptor S1P1, the expression of these cad-
herins is induced via activation of small GTPase Rac in
endothelial cells (Paik et al., 2004). N-Cadherin is found
in so-called peg-socket contacts which are junctional
complexes between endothelial cells and pericytes,
whereas VE-cadherin is regularly found in junctional
complexes between neighboring endothelial cells. Inhibi-
tion of S1P1 signaling in knockout mice regularly leads
to decreased pericyte/smooth muscle cell coverage of
blood vessels, again causing vascular abnormalities and
gestational lethality (Liu et al., 2000).
The transforming growth factor beta (TGF-b) is
another established factor inducing vascular stability as
well as vessel maturation. TGF-b and TGF-bR2 knock-
out mice develop defects of the vascular wall which have
been attributed to lacking inhibition of endothelial pro-
liferation and migration (Oshima et al., 1996; Li et al.,
1999). It has been suggested that pericytes are involved
in TGF-b mediated vascular stability through the activa-
tion of this cytokine (Antonelli-Orlidge et al., 1989; Sato
and Rifkin, 1989), but a definitive proof of this concept
is still lacking.
Contribution to Angiogenesis
and Neovascularization
The significant role of brain pericytes in angiogenesis
and neovascularization has also been demonstrated in
models of traumatic brain injury and brain hypoxia
which are strong stimuli for angiogenesis (Dore-Duffy
et al., 1999). In ultrastructural studies, pericytes were
shown to be the first population responding to brain hy-
poxia in cats. First morphologic alterations were already
observed as soon as 2 h after brain hypoxia. At this time
no other population of the BBB interface including
astrocytes and endothelial cells exhibited visible
changes. These alterations in pericyte morphology were
interpreted as initial steps of migration as the abluminal
surface of the cells formed characteristic ‘‘peaks" point-
ing and extending towards the parenchyma. Simultane-
ously, the luminal basement membrane between peri-
cytes and endothelial cells began to thicken while the
abluminal one thinned out (Gonul et al., 2002). Similar
findings have been reported after traumatic brain injury.
The investigators observed thickened luminal basement
membranes and ruffled borders at the abluminal side,
followed by elongation of pericytes and the disappear-
ance of the basal lamina at the leading edge of migrat-
ing cells. In addition, using the model of traumatic brain
injury migration of pericytes was confirmed by calculat-
ing the ratio of pericytes versus endothelial cells, which
dropped from 1:5 to 1:10-12 (Dore-Duffy et al., 2000). It
has been shown that activation and migration usually
involves the expression of urokinase plasminogen activa-
tor (uPA) and its receptor (uPAR) on migrating cells
(Blasi, 1999; Washington et al., 1996). Consequently, mi-
gratory pericytes express these molecules at the mRNA
and at the protein level showing a characteristic distri-
bution of uPAR at the leading tips of migrating cells
(Dore-Duffy et al., 2000). As the complex of ligand and
receptor represents an active protease, its distribution
on the leading cellular processes might be a crucial pre-
requisite to digest the glial basement membrane in
order to overcome this barrier on the way into the neu-
ropil. Interestingly, Dore-Duffy et al. demonstrated that
pericytes remaining in position exhibited signs of cyto-
plasmic and nuclear degeneration. It is important to note
that the processes of such migratory pericytes were often
found to be interdigitated with synaptic complexes. This
has been interpreted as a sign of synaptic stripping, a
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concept of active displacement of synapses originally
describing a microglial response which may protect the
neurons from excess glutamate levels (Blinzinger and
Kreutzberg, 1968; Trapp et al., 2007). An alternate expla-
nation for this observation is that retraction of synapses
is solely driven by neurons, and the appearance of peri-
cytic processes is a secondary event.
VEGF, which is produced by pericytes under hypoxic
conditions, is a crucial molecule in the dialogue between
pericytes and the endothelium (Yamagishi et al., 1999).
Its effect on vessel formation has been studied in a
chicken chorioallantoic membrane assay. Here, VEGF
induced CD31-positive angiogenic sprouts to display
alpha smooth muscle actin (a-SMA) and desmin express-
ing cells of pericytic phenotype. Since CD31 is an estab-
lished marker for mature and embryonic endothelial
cells, the assumption is that endothelial cells transform
into pericytes or smooth muscle cells and that VEGF
plays an important role in this transformation (Hage-
dorn et al., 2004). Moreover, the number of pericytes
covering newly formed capillaries can be increased via
VEGF, which correlates with the dose of VEGF treat-
ment (Benjamin, 1998).
Finally, the role of pericytes in angiogenesis has also
been supported by targeting NG-2 (nerve/glial antigen 2,
NG-2) which is expressed by immature pericytes. Both
blocking by antibodies as well as knocking out the gene
encoding NG-2 abrogated vascular growth in various
models of induced angiogenesis (Ozerdem and Stallcup,
2003, 2004; Ruiter et al., 1993). However, it should be
kept in mind that NG-2 is also expressed on other cell
types of the CNS such as oligodendrocyte precursors
(Diers-Fenger et al., 2001; Trotter, 2005).
As pericytes are critically involved in angiogenesis
and neovascularization, they have been suggested as pu-
tative drug targets in the pharmacological therapy of
tumors. In tumor models, antiangiogenic treatment
directed against endothelial cells using VEGF inhibitors
leads to regression of tumor vessels and decreased tu-
mor size (Baluk et al., 2005). Unfortunately, removal of
VEGF inhibition caused massive tumor re-growth. This
was explained by the fact that after treatment regressed
tumor vessels were indeed depleted of endothelial cells
but pericytes and empty basement membrane sleeves of-
ten remained in position (Baluk et al., 2005). These
structures are now likely to provide a scaffold for the
rapidly re-growing tumor vessels, which lead to the idea
of using the synergistic effect of anti-endothelial and
anti-pericytic drugs in tumor therapy. This was investi-
gated in models using C6 rat tumor cells where a regres-
sion of 40% of the tumor blood vessels was achieved by
targeting both cell types, whereas a solitary endothelial
targeting by VEGFR-2 inhibitors did not reveal signifi-
cant changes (Erber et al., 2004). Another study demon-
strated that targeting pericytes via PDGF receptor
antagonists readily increased the effect of Taxol, an
anti-mitotic drug and decreased tumor size by 52% in
comparison to the treatment of Taxol alone (Pietras
et al., 2002). Thus, future targeting of pericytes might
crucially enhance the outcome of tumor therapy.
The Old Tale and Recent Observations of
Pericytes as Regulators of Cerebral Blood Flow
The idea of pericytes impacting on vascular blood flow
dates back to Rouget. In 1873, he was the first to
describe branched, non-pigmented cells on the capillary
wall (Fig. 4A) and regarded them as contractile elements
already distinguishing them from migratory leucocytes
(Rouget, 1873, 1874, 1879). The term pericytes was later
coined by Zimmermann in 1923 (Zimmermann, 1923).
Zimmermann distinguished three subgroups of pericytes
including transition forms to ordinary smooth muscle
cells of the tunica media (Fig. 4B). In his 1902 work
[The Musculature of Capillary Blood Vessels], Mayer
(1902) also suggested pericytes to merge1 into smooth
muscle cells of the tunica media of arteries. In response
to Mayer’s claim of having detected contractile pericytes,
Vimtrup (1922) refuted this statement by summarizing
Rouget’s and later findings. In addition, he added some
of his own observations concerning the contractibility of
capillary vessels. Studying capillaries in tails of different
young living larvae, he noted that ‘‘the contraction of
capillaries begins at one of these cells (pericytes),
spreading in both directions, at first slowly, later signifi-
cantly faster’’ (Vimtrup, 1922).2 Using a simple method,
Vimtrup ensured that he in fact analyzed capillaries: he
confined his studies to areas where the afferent arterio-
les and the efferent venules were clearly visible, thus
allowing unequivocal identification of the capillary seg-
ment in-between. In appreciation of Rouget’s work, he
termed the observed contractile population at capillaries
‘‘Rouget cells’’ (Vimtrup, 1922). This term remained
prominent for decades and eventually labeled all peri-
cytic populations irrespective of the type of vessel they
belonged to.
Since then the discussion concerning the ability of
pericytes to regulate cerebral blood flow never ceased.
Data suggested that they respond to vasoactive substan-
ces such as nitric oxide, prostacyclin, angiotensin II, and
endothelin-1 as they express respective receptors (Chak-
ravarthy and Gardiner, 1999; Dehouck et al., 1997;
Healy and Wilk, 1993). Additional prerequisites of con-
traction are actin and myosin filaments which exist as
smooth muscle and non-smooth muscle isoforms. Both,
the first and the latter, were found in cerebral pericytes
(Herman and D’Amore, 1985). However, the expression
of these elements seems to vary from species to species.
In embryonic chicken, all pericytes express a-SMA, but
1Original text: Was sich insbesondere an letzterem Objecte in aller Klarheit dem-
onstrieren l€asst, ist die Thatsache, daß ein continuierlicher €Ubergang vorliegt von
glatten Musekelzellen der Arterienwand, die erst noch Spindeln darstellen, die
sich mehrfach teilen und um das Gef€aßrohr herumschlingen, wobei der Kern senk-
recht zur Gef€aßachse steht, bis zu mehrfach verzweigten Zellen (Pericyten), deren
Kern an den feinsten Capillaren, die aber noch aus Zellhaut und Grundhaut beste-
hen, nunmehr parallel zur L€angsachse steht und von beiden Seiten feine F€aden
entsendet. English translation: Considering the last object, we can clearly demon-
strate that there is a continuous transition of fusiform smooth muscle cells of
arteries to multiple branched cells of the capillary wall (pericytes). While the nu-
cleus of smooth muscle cells is transversally aligned to the axis of the vessel, the
nucleus of the latter (pericytes) is now aligned longitudinally to the vessel axis.
2Original text: Die Verengerung beginnt an einer der erw€ahnten Zellen und ver-
breitet sich von da aus nach beiden Seiten hin, anfangs langsam, sp€ater bedeutend
schneller.
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in rat and mouse this is not the case (Gerhardt et al.,
2000; Hellstrom et al., 1999). Moreover, the expression
varies along the segments of the vascular tree. In mice,
pericytes surrounding capillaries with a diameter of less
than 10 lm do not show a-SMA activity, whereas peri-
cytes of larger vessels like arterioles or post-capillary
venules are regularly immune positive for a-SMA
throughout the brain (Alliott et al., 1999; Nehls et al.,
1991). This differential expression pattern is very likely
to reflect functional differences of pericytes. It is note-
worthy that in capillaries, pericytes and the astroglial
endfeet of the glia limitans are separated by a basement
membrane only, while in larger vessels they are topo-
graphically separated by the perivascular spaces. This
loss of contact may crucially impact on the gene expres-
sion of pericytes, but detailed knowledge regarding
the role of astrocytes in pericytes differentiation is still
lacking.
Fig. 4. Seminal contributions. (A) Rouget’s original drawing from
his 1873 paper. He describes branched non-pigmented cells of the capil-
lary walls which he divided into amoeboid migratory cells (arrow) and
fusiform contractile cells (arrow heads) (B) The term ‘‘pericytes’’ was
coined by Zimmermann in 1923, who distinguished three different sub-
types depending on the type of vessel pericytes are located at, but al-
ready considered the existence of a continuum with countless forms of
differentiation. (C) Studying pericytes has always been inflicted by dif-
ficulties in identification. Zimmermann foresaw that major progress in
understanding pericyte functions will require tools to specifically trace
them. As such tools are now available, such progress can be expected in
the near future (B).
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It is widely believed that blood flow is regulated in
precapillary arterioles. Therefore it is interesting to note
that 65% of the noradrenergic innervation of CNS blood
vessels terminates in the neighborhood of capillaries
(Cohen et al., 1997). A recent study using live-imaging
techniques in rat retinal and cerebellar slices demon-
strated that ATP and noradrenalin induces the constric-
tion of capillaries. Addition of GABA-blockers also leads
to the constriction of the corresponding capillary, while
the application of glutamate suppresses this process.
This response is confined to areas where pericytes re-
side, strongly supporting that their active contraction is
driving this response (Peppiatt et al., 2006). Thus, in
continuation of Rouget’s, Zimmermann’s, and Vimtrup’s
approach to observe living vessels, advanced techniques
of live-imaging now support their original ideas and
provide first mechanistic insights.
CONCLUDING REMARKS
By definition, pericytes are part of the vascular wall
where they are ensheathed by the outermost basement
membrane. They exhibit apparent heterogeneity in
regard to their immune phenotype and morphology,
which may reflect the existence of at least two subpopu-
lations: a smooth muscle cell-like contractile element
and a phagocyte-like cell type. It is currently unknown
whether these populations derive from different precur-
sors or differentiate into alternate directions depending
on their position in the vascular tree or additional fac-
tors such as ischemia and infection. A closer look at var-
ious studies addressing this issue revealed that pericytes
were improperly identified or clearly mixed up with ad-
jacent populations such as leptomeningeal mesothelial
cells, perivascular phagocytes, and juxtavascular micro-
glia rendering the interpretation of the respective data
difficult. Here, we show that, although not trivial, it is
possible to precisely identify pericytes within histological
sections irrespective of their origin and differentiation
state. Applying electron microscopy and semi-thin sec-
tions in combination with immunocytochemistry will
minimize confusion and help further unraveling their
functions in health and disease. However, studying peri-
cytes during the time course of pathology is still inflicted
by their potential ability to leave their defined position
in the vascular wall (Dore-Duffy et al., 2000; Gonul
et al., 2002), thus inhibiting clear-cut morphological
detection. Recent advances in live-imaging and genetic
cell tracking now provide tools to eventually determine
their function(s) in situ (Fig. 4C).
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Abstract Recent studies demonstrated that primary
immune responses can be induced within the brain
depending on vessel-associated cells expressing markers of
dendritic cells (DC). Using mice transcribing the green
fluorescent protein (GFP) under the promoter of the DC
marker CD11c, we determined the distribution, phenotype,
and source of CD11c? cells in non-diseased brains. Pre-
dilection areas of multiple sclerosis (MS) lesions
(periventricular area, adjacent fibre tracts, and optical
nerve) were preferentially populated by CD11c? cells.
Most CD11c? cells were located within the juxtavascular
parenchyma rather than the perivascular spaces. Virtually
all CD11c? cells co-expressed ionized calcium-binding
adaptor molecule 1 (IBA-1), CD11b, while detectable
levels of major histocompatibility complex II (MHC-II) in
non-diseased mice was restricted to CD11c? cells of the
choroid plexus. Cellular processes project into the glia
limitans which may allow transport and/or presentation of
intraparenchymal antigens to extravasated T cells in peri-
vascular spaces. In chimeric mice bearing CD11c-GFP
bone marrow, fluorescent cells appeared in the CNS
between 8 and 12 weeks after transplantation. In organo-
typic slice cultures from CD11c-GFP mice, the number of
fluorescent cells strongly increased within 72 h. Strikingly,
using anti-CD209, an established marker for human DC, a
similar population was detected in human brains. Thus, we
show for the first time that CD11c? cells can not only be
recruited from the blood into the parenchyma, but also
develop from an intraneural precursor in situ. Dysbalance
in their recruitment/development may be an initial step in
the pathogenesis of chronic (autoimmune) neuroinflam-
matory diseases such as MS.
Keywords Neurodegeneration  Alzheimer 
Innate immunity  Multiple sclerosis (MS)  Microglia 
Immune privilege
Introduction
Based on the observation that many foreign antigens, such
as allografts or heat-killed Bacillus Calmette-Gue´rin
(BCG), inoculated into the parenchyma are tolerated [31,
35, 43] the brain has been addressed as an ‘‘immunologi-
cally privileged’’ site [4, 8, 14]. The concept of immune
privilege has often been misapprehended as describing a
state of ignorance, although Medawar had already shown
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that the observed tolerance to ‘‘foreign’’ antigens within the
brain parenchyma can readily be broken by peripherally
exposing the same antigen [3, 35]. Therefore, he concluded
‘‘that skin homografts transplanted to the brain submit to,
but cannot elicit an immune state’’ and that ‘‘a lymphatic
drainage system is necessary for immunity to be called into
being’’ [35]. Such drainage is now established for solutes
involving pathways such as perivascular spaces, the cri-
broid plate, and the perineural sheath [10, 61]. Recently,
myelin-associated as well as axonal antigens have been
detected in cervical lymph nodes during experimental
autoimmune encephalitis (EAE) [11], multiple sclerosis
(MS) [12] and after axotomy [37, 59], but it is unclear
whether they are drained passively within the cerebrospinal
fluid (CSF) or transported actively out of the brain by a sort
of dendritic (DC) or monocytic cell. Such transportation
would conflict with the predominant current view that
antigen-presenting cells (APC) do not leave the paren-
chyma of the brain. However, cells expressing DC/APC
markers have been detected in the meninges, the choroid
plexus [30, 33, 34], and the cerebrospinal fluid [41, 42] and
they appear in the parenchyma under inflammatory con-
ditions [13, 16, 39, 46, 47, 51, 52, 55].
Recently, it has been shown that the induction of neur-
oinflammation depends on antigen-presenting dendritic
cells associated with brain vessels [16, 32], but their
topographic localization and distribution remained
unknown. This was at least in part due to the problem that
currently available antibodies raised against DC markers
such as CD11c and CD205 provided no or questionable
signals within the normal mouse brain.
Here, we used mice expressing green fluorescent protein
(GFP) under the control of the CD11c promoter itgax for
an in-depth analysis of the CD11c? population within the
central nervous system (CNS) [19]. In line with previous
reports, we found numerous ramified CD11c? cells within
the meninges and the choroid plexus. However, we report
that they also reside within the brain, the spinal cord, and
the optic nerve, where they are mostly located within the
parenchyma from where they extend processes to the glia
limitans. Since re-stimulation of T cells by their cognate
antigen in perivascular spaces is indispensable for their
progression across the glia limitans [4, 58], it may be the
presence of CD11c? cells at the glia limitans rendering
them crucial for the onset of neuroinflammation [16].
At present, the origin of the DC observed in (autoim-
mune) neuroinflammation is unclear. They may either
derive from microglia stimulated with granulocyte mac-
rophage colony-stimulating factor (GM-CSF) [49] or
infiltrate the parenchyma from the blood along with other
leukocytes [16, 39]. Using slice cultures derived from p3
and adult CD11c-GFP mice and chimeras grafted with
CD11c-GFP bone marrow, we demonstrate for the first
time that CD11c? cells can differentiate from an intrapa-
renchymal precursor in situ and—in principle—can be
recruited from the systemic circulation. Due to the irradi-
ation used to create bone marrow chimeras, the latter
finding, however, must be interpreted with care since
Mildner et al. [36] demonstrated that shielding of brain
areas during irradiation specifically blocks infiltration into
the respective regions. Finally, we identified a population
reflecting the intraparenchymal location of CD11c? cells
in human brains using the DC-marker CD209.
Materials and methods
Mouse strains and housing
CD11c-diphtheria toxin receptor (DTR)-GFP transgenic
(tg) mice [19], i.e., mice expressing GFP under the control
of the CD11c promoter itgax, on a C57BL/6 background
were purchased from Charles River (Charles River Labo-
ratories, Inc., Wilmington, MA) and housed under standard
conditions with free access to food and water. Care was
been taken to minimize any pain and discomfort to ani-
mals. All experiments were performed after approval by
the Animal Ethical Committee according to German leg-
islation on animal experiments.
Perfusion and fixation
Animals (n = 30; 7–21 weeks of age) were killed and
transcardially perfused with 100 ml 0.9% NaCl (Appli-
Chem. Darmstadt, Germany) followed by 100 ml of a
fixative containing 4% paraformaldehyde (PFA) (Merck,
Germany) in 0.1 M phosphate buffered saline (PBS; pH
7.4). Brains were removed and post-fixed overnight in the
same fixative and cut on a vibratome (30–50 lm sections)
(Microm, HM 650V) or incubated in a solution of 30%
sucrose (Fluka Biochemika, Germany) in 0.1 M phosphate
buffer (PB; pH 7) for 24 h. These sections were embedded
in Neg-50 medium (Richard-Allan Scientific, Kalamazoo,
MI), snap-frozen in -80C cold methylbutane (Roth,
Karlsruhe, Germany), and cut further into 10–20 lm
cryostat sections. For semithin sections and electron
microscopy, the fixative contained 4% sucrose and 0.2%
glutaraldehyde (AgarScientific, United Kingdom) in car-
bonate buffered PFA. The brains were removed and post-
fixed over night in the same solution.
Immunostaining for (confocal) fluorescence
microscopy
For the immunocytochemistry, slices were fixed at 1, 24,
48 and 72 h in 4% paraformaldehyde overnight at 4C.
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Subsequently, the slices were stored in 0.8 M saccha-
rose-solution over 2 weeks at 4C. Afterwards, the slices
were cut into 10 lm sections with a cryostat.
Unspecific binding was blocked using 10% normal
goat serum (NGS) (Chemicon, Temecula, CA) and 0.5%
Triton X-100 (VWR, Prolabo, Darmstadt, Germany) in
PB. After incubation in this solution for 30 min, sections
were incubated at ?4C overnight in PB containing
1% NGS and 0,5% Triton X-100 and the respective
primary antibodies: polyclonal anti-ionized calcium-
binding adaptor molecule 1 (anti-IBA-1) (1:1,000; rabbit
anti mouse; WAKO Chemicals, Neuss, Germany); anti-
CD11b (1:100; rat anti mouse; Leinco, St. Louis, MO);
anti-major histocompatibility complex II (anti-MHC-II)
(1:100; rat anti mouse; BD, Heidelberg, Germany); anti-
pan-laminin (1:200; rabbit anti mouse; DakoCytomation,
Denmark); anti-glial fibrillary acidic protein (anti-GFAP)
(1:1,000; mouse anti mouse; Chemicon, Temecula, CA).
After several washes in PB, sections were incubated for
90 min at room temperature in PB containing 1% NGS
and 0.5% Triton X-100, and the corresponding secondary
antibody (Alexa 350, Alexa 488, Alexa 568, or Alexa
688; all 1:250; Invitrogen, Karlsruhe, Germany). For
nuclear staining the Hoechst reagent (Sigma, Steinheim,
Germany) was used according to the manufacturer’s
protocol. Sections were embedded in fluorescence
mounting medium (DakoCytomation, Denmark).
Diaminobenzidine (DAB)-staining
For DAB staining, slices were incubated in 1% Na-
borohydride (Sigma, St. Louis, MO) to reduce back-
ground fluorescence. Lipids were unhinged by short
incubation in an ascending and descending alcohol series
(20–30–40–30–20%). Unspecific binding was blocked
using 5% bovine serum albumin (BSA) (Biomol, Ham-
burg, Germany) in PB for 60 min. Sections were
subsequently incubated with the primary antibody
(polyclonal goat anti-GFP 1:1,000; Acris, Hiddenhausen,
Germany) and 1% BSA dissolved in PB at 4C over-
night. Section were then washed several times in PB and
incubated in a solution containing 1% BSA and the
biotin-coupled secondary antibody (1:200; Vector-Labo-
ratories, Wertheim-Bettingen, Germany) in PB for
90 min at room temperature. Binding of the primary
antibody was visualized using an avidin–biotin (ABC) kit
(Vector-Laboratories, Wertheim-Bettingen, Germany)
with DAB as chromogen according to the manufacturer’s
instructions. Slices were dehydrated and embedded in
Durcupan (ACM Fluka, Sigma-Aldrich, Gillingham,
UK). Semithin and ultrathin sections were cut using a
Leica Ultracut (Ultracut UCT, Leica).
Organotypic slice cultures
Organotypic slice cultures were prepared from either 3-day-
old or adult CD11c-DTR-GFPtg mice (Jackson Laborato-
ries, Boston, MA, USA) as previously described [24]. In
brief, mice were perfused with saline to eliminate blood
leukocytes from the circulation. After decapitation, the
brain was rapidly removed under sterile conditions and
placed in ice-cold preparation medium consisting of 50%
minimum essential medium (MEM) (Gibco, Karlsruhe,
Germany), 49 ml aqua pro inject, with 2 mM L-glutamine
(Gibco, Karlsruhe, Germany) at pH 7.35. The hippocampi
were taken from the brain and cut into 350 lm thick vertical
slices on a tissue chopper (Technical Products International,
St. Louis, MO, USA). Subsequently, the slices were cul-
tured on Millipore cell culture inserts (pore size 0.4 lm;
Millipore, USA) in six-well plates containing cultivation
medium. The sterile medium contained 25% MEM, 25%
basal medium eagle (BME) (Gibco, Karlsruhe, Germany),
25% heat-inactivated normal horse serum (Gibco), 20.9 ml
aqua pro inject, 2 mM L-glutamine, 0.65% glucose-20
(Braun, Melsungen, Germany), at pH 7.2. The organotypic
slice cultures were incubated at 37C in a humidified
atmosphere with 5% CO2 for 1, 24, 48 and 72 h. The culture
medium was changed every 48 h (n = 10). To exclude that
exogenous effects induce the differentiation of dendritic
cell in the slice culture, we performed the same experiments
with serum-free medium using p3 and adult animals
(n = 10). The serum-free medium contained (for 100 ml)
37.5 ml MEM, 20.9 ml aqua pro inject, 37.5 ml BME with
2 mM glutamine and 0.65% glucose-20 (Gibco, Karlsruhe,
Germany) at pH 7.2 (n = 3).
Irradiation of bone marrow chimeric mice
CD11c-GFP mice were killed by cervical dislocation. Bone
marrow (BM) cells were isolated by flushing femur and
tibia bones with Dulbecco’s Modified Eagle Medium
(DMEM) containing 1% penicillin/streptomycin and 1%
fetal bovine serum (all from GIBCO, Invitrogen, Kar-
lsruhe, Germany) filtered through a 40 lm cell strainer
(BD, Heidelberg, Germany). C57BL/6J wild type (wt)
recipient mice were lethally irradiated with 11 Gy (split
dose 2 9 5.5 Gy) and intravenously injected with
4–6 9 106 BM cells. On each of days 5, 15, 28, 46, 75, 105
and 161 (15 and 23 weeks; n = 4) after transplantation
mice were killed for histological analysis.
Entorhinal cortex lesion (ECL)
Stereotaxic lesioning of the left entorhinal cortex was
performed as described in detail elsewhere [6, 25]. In brief,
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mice were anaesthetized with a mixture of ketamine (20%)
(Cura Med, Germany) and Rompun (8%) (Bayer Vital,
Germany) (10 ll/g body weight). They were then fixed in
an stereotactic apparatus (Kopf Instruments, Tujunga, CA)
and the eyes were protected with a humid soft tissue. For
ECL, the left entorhinal cortex was lesioned using a 2 mm
broad knife. After exposing the skull the following coor-
dinates measured from k (where the longitudinal and the k
suture meet) were used: anteroposterior ?0.4 mm, lateral
?1 mm and dorsoventral, down to the base of the skull.
The wound was carefully sutured and the animal was
placed back in its cage. Three days after entorhinal lesion,
animals were killed and perfused as described above.
Microscopy
To analyze the colocalization of GFP? cells with the
expression of common microglia markers and to determine
the distribution of the GFP? cells in the slice, a Leica TCS
SL laser scanning microscope with was used. 3D-recon-
struction was performed with Volocity 3 software
(Improvision, Tu¨bingen, Germany) (n = 3). Fluorescent
stainings and semithin-sections were studied using an
Olympus BX51 fluorescence and light- microscope or a
Zeiss Axiovert 100 M LSM510 confocal microscope. For
analysis of the 3D-extension of CD11c-GFP cells within
slices and the stainings of BM-chimeras, an Olympus
Fluoview FV1000 was used. The 3D-reconstruction was
performed with Imaris software. Electron-microscopy was
performed using a Zeiss EM109.
Human tissues
Formalin-fixed and paraffin-embedded human autopsy
material with or without neuropathological alteration was
used. All cases underwent detailed neuropathologic exam-
ination. Informed consent for autopsy and subsequent use of
tissue for research purposes was given. To mark human DC
a primary antibody to human DC-SIGN (CD209; R&D
Systems; 1:10 dilution) was used upon ethylenediaminete-
traacetic acid (EDTA)-driven antigen retrieval. The
immunohistochemical staining was carried out on an auto-
mated Benchmark staining apparatus (Ventana Medical
Systems/Roche) following the manufacturer’s guidelines.
Results
Distribution of CD11c-GFP cells throughout the CNS
(Fig. 1)
Serial sections of brain, spinal cord, and optic nerve
revealed a consistent rather than random distribution
pattern of CD11c-GFP cells (Fig. 1a). In the brain, they
were preferentially situated within the tela of the choroid
plexus, beneath the ependyma of the lateral ventricles,
along the adjacent corpus callosum and the fornix (Fig. 1b–
d). Regularly, but at lower numbers, CD11c-GFP cells
were also present in the white matter of the olfactory bulbs,
the brain stem and the cerebellum. Such preferential
location within the white matter was also evident in the
spinal cord (Fig. 1e), where the largest numbers were
found along the spinobulbar tract and the lateral fibre
tracts, while the spinal nerves were not populated by
CD11c-GFP cells (Fig. 1f–h). Importantly, the optic nerve
was found to be densely populated by CD11c-GFP cells
(Fig. 1i, k), while fluorescent cells were extremely rare
within other cranial nerves, e.g. the trigeminal nerve
(Fig. 1l) and the trigeminal ganglion.
Parenchymal, but not choroid plexus CD11c-GFP cells
express microglial markers but lack MHC-II (Fig. 2)
At higher magnification CD11c-GFP cells exhibited rami-
fied morphologies with more plump processes in the
ependyma of the lateral ventricles and tiny ramifications
within fibre tracts. Counterstaining with IBA-1 and CD11b
revealed that almost all CD11c-GFP cells expressed these
microglial markers. The ratio of CD11c-GFP cells among
all microglia stained with IBA-1 or CD11b ranged between
none or occasional cells (e.g., cortex) and a maximum of
up to two thirds (optic nerve). MHC-II was expressed at
detectable levels by CD11c-GFP cells only in the choroid
plexus. In contrast to all other regions studied, CD11c-GFP
cells of the plexus did not regularly express IBA-1 and
CD11b (Fig. 2g–i). Meningeal and perivascular macro-
phages expressed MHC-II in all brain areas (Fig. 2c–m).
CD11c-GFP cells are preferentially localized
in the juxtavascular neuropil (Fig. 3)
As anticipated from fluorescence microscopy and a previous
report [16], CD11c-GFP cells were regularly found in close
vicinity to blood vessels (Fig. 3a) raising the question of
whether they are part of the vascular wall, reside in peri-
vascular spaces (i.e., the compartment between the vascular
basement membrane and the glia limitans) or within the
juxtavascular parenchyma (i.e., the neuropil beyond the glia
limitans) [4, 40] (Fig. 3b). To address this issue, the borders
between these three compartments (vascular wall, perivas-
cular space, and juxtavascular parenchyma) were
demarcated using GFAP and/or laminin antibodies. As the
vascular and the glial basement membranes differ in their
laminin contents [53], an anti-pan-laminin serum was used
allowing simultaneous detection of both membranes
(Fig. 3d, e). To unequivocally distinguish the perivascular
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space from the parenchyma, the localization of identified
CD11c-GFP cells was further analysed in semi- and ultrathin
sections (1.0 and 0.055 lm, respectively). In laminin-stained
samples, most CD11c-GFP cells appeared to reside within
the juxtavascular parenchyma (Fig. 3a). This finding was
confirmed in semithin sections (Figs. 3c, 4c). Only occa-
sional cells were located within perivascular spaces. In
contrast to the parenchymal population, these cells lacked
tiny ramifications (Fig. 3d–e).
CD11c-GFP cells participate in the glia limitans
organization (Fig. 4)
Confocal analysis of sections stained for laminin or GFAP
suggested that processes of CD11c-GFP cells participate in
the formation of the glia limitans (Fig. 4a, b). The same
was observed in semithin sections, where GFP was stained
with a polyclonal antiserum (Fig. 4c). In fact, electron
microscopical analysis revealed that CD11c-GFP cells
directly attach to the basement membrane of the glia lim-
itans (Fig. 4d) thus representing an integral element of this
glial barrier.
Origin of CD11c-GFP cells (I): appearance of CD11c?
cells in organotypic brain slices (Figs. 5, 6, 7)
The origin of CD11c? dendritic cells in inflamed neural
tissue is currently unclear. They may either be recruited
from blood or derive from intrinsic (microglial) precursors.
To test the latter possibility, we prepared organotypic slice
Fig. 1 Distribution of CD11c-
GFP cells throughout the CNS.
a–d Distribution of CD11c-GFP
cells in the forebrain. a Four
horizontal brain hematoxylin
and eosin-stained sections from
different levels schematically
show the typical distribution of
CD11c-GFP cells. Sites of
evident accumulation included
the periventricular/
subependymal area, the alveus,
fimbria, the choroid plexus, and
the corpus callosum. b–
d CD11c-GFP cells are shown
at sites of typical accumulation
in 16 lm cryosections as
indicated by frames in
a (sections 2 and 3).
b Subventricular zone of the
frontal pole of the lateral
ventricle; c fornix; d choroid
plexus/tela choroidea of the
third ventricle. e–h Distribution
of CD11c-GFP cells in the
spinal cord. The frames depicted
in e are shown under high
magnification in f–h. f The
spinothalamic tract is densely
populated by CD11c-GFP cells.
The white line indicates the
surface of the spinal cord.
g Many CD11c-GFP cells are
regularly found in the
spinobulbar tract. h No cells
were found in the spinal nerve
and its roots, visualized with
Hoechst staining. i, k, l While
the optic nerve (i, k) is densely
populated by CD11c-GFP cells,
the trigeminal nerve (l) and
other cranial nerves contain
only very few fluorescent cells
(arrow in l)
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cultures obtained from CD11c-GFP mice and searched for
GFP? cells in living cultures using an epifluorescence
microscope. Despite the relatively low resolution of this
mode of observation, it was already evident that the
number of GFP-expressing cells strongly increased over
time. For a more detailed analysis of the respective cells,
slices were subsequently fixed at various time points and
cryosections were prepared for immunocytochemistry.
As shown in Fig. 5a–c, few or no fluorescent cells were
visible in slices from p3 animals at 1 h after incubation. At
24 h, numerous GFP? cells could be detected in all cul-
tures (Fig. 5d–f). These cells were located throughout the
whole width of the slices which was evident in cross
sections cut perpendicularly to the surface of the slice
(Fig. 5f). Cryosections of these slices revealed that the
fluorescent cells exhibited ramified morphologies and
stained positive for the microglial markers MAC-1 and
IBA-1 (Fig. 6). No additional increase of GFP? cells was
apparent at 48 and 72 h.
An important question was whether the induction of
CD11c on cells within slice cultures was restricted to the
early postnatal phase. Therefore, we prepared acute brain
slices from adult (8–12 weeks old) mice and studied the
appearance of fluorescent cells in these tissues. Again,
fluorescent cells were rare or absent directly after incuba-
tion (Fig. 5g–i), but numerous cells were found after 24 h
Fig. 2 Parenchymal, but not choroid plexus CD11c-GFP cells
express microglial markers but lack MHC-II. Brain (a–c), spinal
cord (d–f), choroid plexus (g–l) and optic nerve (k–m) of CD11c-GFP
mice were counterstained with antibodies for the microglial markers
IBA-1 (a, d, g, k) and CD11b (b, e, h, l) and for MHC-II (c, f, i, m).
CD11c-GFP is shown in green, IBA-1, CD11b, and MHC-II in red,
nuclei stained with Hoechst are shown in blue. The inserts represent
one characteristic cell for each staining. Note that the antibody against
MHC-II strongly labels meningeal macrophages, but not intraparen-
chymal GFP-expressing cells.Green arrows in g and h point to CD11c-
GFP cells, which are negative for either IBA-1 (d) or CD11c (e)
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in vitro (Fig. 5j–l). Thus, just like in the early postnatal
phase, adult brain tissue apparently contains a cell type
with the potential to express CD11c.
As shown in Fig. 7, 3D-reconstruction of the CD11c-
GFP cells revealed tiny extensions of up to 35 lm with
rare or invisible secondary ramifications. Due to the
counterstaining of nuclei with Hoechst, it also became
apparent that the cells were clearly located within the
parenchyma rather than being part of (peri-)vascular
remnants (Fig. 7).
Fig. 3 CD11c-GFP cells are preferentially localized in the juxtavas-
cular neuropil. a Confocal 3D-reconstruction of CD11c-GFP cells and
their relation to a brain vessel (stained for pan-laminin in red) in a
50 lm vibratome section. As described previously [16], all cells are
to be vessel-associated raising the question of whether they are in the
juxtavascular parenchyma or in the perivascular space. Both
compartments seem to be populated (arrowhead juxtavascular, arrow
perivascular), but it is impossible to unequivocally distinguish
between the two in these sections. b Schematic illustration of the
different compartments of the neurovascular interface. The vascular
wall represents the first compartment and consists of endothelial cells,
pericytes and (if present) smooth muscle cells of the tunica media.
The second is the perivascular (Virchow/Robin) space which harbors
perivascular macrophages and leptomeningeal mesothelial cells. It is
on the one side bordered by the basement membrane of the vascular
wall, and by the basement membrane of the glia limitans on the other.
The third compartment is the juxtavascular parenchyma starting
beyond the astrocytic endfeet forming the glia limitans. c The
existence of juxtavascular, and thus intraparenchymal CD11c-GFP
cells was confirmed in semi-thin sections (1.0 lm) in which GFP was
visualized with an antibody and DAB staining. The neuropil is
counterstained with toluidine-blue. The vast majority of CD11c-GFP
cells turned out to be located within the juxtavascular parenchyma. d,
e In addition, scattered individual cells cells were also found in
perivascular spaces depicted either by laminin staining (red) to show
the outer vascular and parenchymal basement membranes (arrows)
and thus the perivascular space in d or by combined laminin (red) and
GFAP (blue) staining. The insert in d shows the same cell after
cutting for semithin analysis which clearly confirms its location
within the perivascular space (arrows point to basement membranes)
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Fig. 4 CD11c-GFP cells
participate in the glia limitans
organization. As shown in
Fig. 3a and c, some cells
seemed to participate in the
organization of the glia limitans.
a This was confirmed by triple
fluorescence analysis depicting
GFAP (blue), laminin (red), and
GFP (green). Note that the
processes of CD11c-GFP cells
intermingle with the astrocytic
endfeet of the glia limitans.
b This was also evident in
sections cutting vessels
perpendicularly to their
longitudinal axis, where CD11c-
GFP processes were found to
embrace the parenchymal
basement membrane (stained
with laminin in red, nuclei
blue). The insert shows a
confocal picture in which
CD11c-GFP processes appeared
to be directly attached to the
parenchymal basement
membrane. c–d This was
confirmed in semithin sections
(c) and ultrastructural analysis
(original magnification 94,400)
(d) of GFP-DAB-stained
sections, where the direct
contact (green arrows) between
GFP-filled cells and the
basement membrane (dotted red
line) could be proven
Fig. 5 Overviews of CD11c-GFP cells in slice cultures. Organotypic
slice cultures were prepared from either p3 (a–f) or adult
(g–l) CD11c-DTR-GFPtg mice and kept in culture for either 1 h
(a–c, g–i) or 24 h (d–f, j–l). CD11c-GFP-expressing cells were rare or
absent at 24 h in p3 (a–c) and adult (g–h) slices. At 24 h, however,
fluorescent cells were abundant in all slices irrespective of whether
they derived from p3 (d–e) or adult (j–l) mice (n = 10). As a proof of
principle, these data demonstrate that neural tissue harbors a cell type
which can be induced to express CD11c. Thus, recruitment across the
blood–brain barrier is not an absolute prerequisite for such cells to
appear in the parenchyma
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Origin of CD11c-GFP cells (II): CD11c-GFP cells can
be recruited from BM (Fig. 8)
In order to test whether the intraparenchymal population of
CD11c-GFP cells can also derive from a precursor of the
BM, C57BL/6J wt mice were lethally irradiated and
transplanted with BM from CD11c-GFP mice. Mice were
killed on each of days 5, 15, 28, 46, 75, 105 and 161 (15
and 23 weeks; n = 4) after transplantation. First intrapa-
renchymal CD11c-GFP cells were detected within the
periaqueductal white matter at 46 days after transplanta-
tion. Subsequently, fornices, brainstem, spinal cord, and
optic nerve were populated. Confocal analyses confirmed
the intraparenchymal localization using laminin to distin-
guish perivascular spaces from the neuropil and
demonstrated the coexpression of microglia/macrophage
markers IBA-1 and CD11b (nearly all cells) and MHC-II
(occasional).
The number of CD11c-GFP cells is not increased
in zones of anterograde axonal degeneration (Fig. 9)
We have previously demonstrated that axonal injury
induced by entorhinal cortex lesion (ECL) causes induction
Fig. 6 Expression of microglial
markers on CD11c-GFP cells.
Immunocytochemistry was
performed in cryosections from
slice cultures of all groups,
constantly revealing that
CD11c-GFP cells were
immune-positive for MAC-1
(a–c) and IBA-1 (d–f). Pictures
shown here derive from an
untreated, p3-slice kept in
culture for 24 h. Note that
MAC-1 (b) is a membrane
protein (CD11b), while IBA-1
(e) and GFP (a, d) are located
within the cytoplasm. The same
observations were made in
slices incubated for 48 and 72 h
(n = 8)
Fig. 7 3D-reconstruction of
parenchymal CD11c-GFP cells.
Various CD11c-GFP cells in a
slice kept in serum-free medium
for 24 h. Nuclei are
counterstained with Hoechst.
The frames in the upper panel
are shown at higher
magnification and in 3D-
reconstruction in a–c. a A cell
showing cardinal branches, but
no secondary ramifications,
reflecting a typical
morphological feature of the de
novo appearing CD11c-GFP
population. b Arrowheads point
to long and tiny extensions.
c Arrowheads point to putative
remnants of small vessels. The
fluorescent cells are clearly
located within the adjacent
parenchyma rather than in the
vascular wall or the perivascular
space
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of CD86 and MHC-II on microglia-like elements [7] as
well as the recruitment of hematogenous cells and their
subsequent transformation into microglia [5]. Similar
findings have been reported by others [2, 26, 62, 63].
Therefore, we speculated that CD11c expression may also
be induced on local microglia or CD11c? hematogeneous
cells may be recruited after ECL. However, an increase in
neither number nor distribution of CD11c-GFP cells was
evident in this setting (Fig. 9a, b). Thus, although axonal
degeneration provides cues for the recruitment of mono-
nuclear cells from the blood and cells expressing the stem
cell marker CD34 [26], CD11c is not found on these
populations.
Anti-CD209 demarks a population of cells in human
brains the distribution of which reflects
intraparenchymal mouse CD11c cells (Fig. 10)
As shown above, CD11c-GFP cells do not only populate
the meninges, the choroid plexus and the perivascular
space, but also reside within the brain parenchyma (Figs. 1,
2, 3, 4). A similar population was identified in human
Fig. 8 CD11c-GFP cells can be recruited from BM. Within a time
period of 48 days to 23 weeks after transplantation of transgenic
CD11c-GFP BM into lethally irradiated wt mice, an increasing
number of ramified CD11c-GFP cells was found in characteristic
locations within the neuropil surrounding the aqueduct (a), brain
stem, fornix (b), fibre tracts surrounding the striatum, white matter of
the spinal cord (c) and the optic nerve (d). Counterstaining of the
basal laminae with laminin (e) demonstrates the intraparenchymal
localization of the CD11c-GFP cells. Further confocal analysis
reveals their regular expression of CD11b (f) and IBA-1 (g) (orange
arrows) and their occasional expression of MHC-II (h)
Fig. 9 The number of CD11c-GFP cells is not increased in zones of
anterograde axonal degeneration. We have previously shown that
myelin-phagocytosing cells in zones of axonal degeneration induced
by entorhinal cortex lesion (ECL) express MHC-II and CD86 [7], and
that mononuclear cells are recruited which subsequently transform
into microglia [5]. a–b To test whether these cells also express
CD11c, we performed ECL in adult mice. The distribution of
microglia in the normal hippocampus is shown in b. A massive
accumulation of IBA-1 (red) cells is visible in the zones of axonal
degeneration in the hippocampus, the molecular layer (ML). How-
ever, these cells did not express CD11c. The frame depicts a CD11c-
GFP cell located at a vessel in the entorhinal cortex which is shown at
higher magnification in the insert
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brains using the DC-marker CD209. These cells were also
located adjacent to blood vessels clearly beyond the glia
limitans within the parenchyma (Fig. 10).
Discussion
In continuation of the work by Hickey and Kimura [18],
two recent papers demonstrate that a population of brain-
based antigen-presenting, CD11c? cells are required and
sufficient to stimulate autoimmune neuroinflammation
within the CNS [16, 32]. Both reports demonstrated that
the population of DC-like elements with the functional
capacity to support T cell activation derives from the sys-
temic myeloid compartment and not from the CNS-
parenchyma, but it was unknown whether they reside in
perivascular spaces or within the parenchyma. Here, we
explored the distribution and localization of such CD11c?
cells within the normal mouse brain, spinal cord and optic
nerve. To this end, we took advantage of a transgenic
mouse strain expressing GFP under the itgax promoter,
since all available antibodies to mouse CD11c reveal weak,
questionable or unspecific staining in cryo-, vibratom-, or
paraffin sections of the brain. This may be explained by
low expression levels of the respective markers under
normal conditions, which may be driven by factors
exclusively present in the normal parenchyma, because DC
were found in the leptomeningeal compartment and during
neuroinflammation using the same antibodies [13, 16, 21,
30, 33, 51] (for review see [42]).
We found that (a) CD11c-GFP cells reside in virtually
all regions of the brain and the spinal cord, (b) they are not
randomly scattered, but their distribution shows a typical
pattern with preferential localization in the periventricular
areas and the adjacent fibre tracts as well as in the optic
nerve and the white matter of the spinal cord, (c) only few
cells are located in perivascular spaces, while the vast
majority resides in the juxtavascular parenchyma from
where they extend processes to the basement membrane of
the glia limitans, (d) CD11c can be induced in cells already
present in the brain, but CD11c cells are also recruited
from the blood, (e) CD209 labels an intraparenchymal
population of cells in human brains with features similar to
the CD11c-GFP cells described herein.
We regard it as the main finding that CD11c-GFP cells
are located within the parenchyma, but extend processes to
the glia limitans. We have previously proposed that neur-
oinflammation involves two differentially regulated steps:
(1) passage of the vascular wall into perivascular spaces,
and (2) progression across the glia limitans into the
Fig. 10 In the human brain
parenchymal DC are present in
the periventricular area. To
analyze the distribution of DC
in human paraffin slices of
different human brains were
stained with CD209, an
established human DC-marker.
In addition to many perivascular
cells, that were described
earlier, a population of
juxtavascular DC reflecting the
intraparenchymal location of the
CD11c? cells of the CD11c-
GFPtg-mice (Figs. 1, 2, 3, 4)
could be detected in the
periventricular regions of the
human brains. a–
b Periventricular white matter.
c Optical nerve (c derives from
a patient with elective necrosis
of the cortex and hippocampus,
a and d from an individual
without brain pathology)
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neuropil [4, 40]. While the first step has been investigated
intensively (for review: [23, 27], much less is known about
the second. The group of Owens was the first to experi-
mentally dissect steps one and two: they found that
elimination of perivascular cells and subsequent induction
of EAE does not interfere with perivascular accumulation
of leukocytes, but completely blocks their progression
across the glia limitans [58]. The same group demonstrated
that the chemokine CCL2 is a major player in driving
recruitment of leukocytes into the parenchyma [2]. In mice
overexpressing CCL2 in the brain, i.p. application of per-
tussis toxin initiates cellular infiltration across the glia
limitans causing weight loss and encephalopathy. Strik-
ingly, treatment of these mice with the broad spectrum
metalloproteinase (MMP) inhibitor BB-94/Batimastat did
not interfere with perivascular infiltration either, but
instead abolished the second step along with clinical
symptoms [57]. Others showed that MMP-2/MMP-9 dou-
ble knock-out mice are resistant to EAE, because they
cannot cleave dystroglycan, which anchors astrocytic
endfeet to the basement membrane of the glia limitans [1].
These studies strongly suggest that expression of MMPs by
either the T cells or macrophages in the perivascular space
is a prerequisite for passage of the glia limitans and the
induction of symptomatic neuroinflammation in EAE.
However, if animals are immunized with horseradish per-
oxidase (HRP) and the same antigen is subsequently
injected into the ventricle, T cells home to HRP-phago-
cytosing perivascular macrophages upon peripheral antigen
boosting, but they do not pass the glia limitans. Again, this
T cell extravasation over the first barrier provided by the
endothelium does not cause clinical symptoms [60].
All these studies are integrated by the view that antigen-
presentation/recognition in the perivascular space may be
necessary, but per se are not sufficient for the induction of
intraparenchymal neuroinflammation [60]. The second step
of neuroinflammation may require presentation of an in-
traparenchymal antigen at the glia limitans itself. In fact,
non-astrocytic processes immune positive for microglial
markers have been demonstrated at the ultrastructural level
by Lassmann [28]. It has often been questioned how T cells
can be re-stimulated within the brain upon adoptive
transfer to cause passive EAE, since their cognate antigen
should not normally be present within perivascular mac-
rophages. Given that the decisive antigen-presenting cell
type expresses CD11c [16, 32] and, as shown here, is
located at the glia limitans, one can picture a scenario in
which, e.g., physiological degradation of myelin and
uptake by local CD-11c? cells causes permanent presen-
tation of its epitopes at the interface between parenchyma
and perivascular space. The arrival of encephalitogenic
Th1/Th17 cells and the accompanying secretion of pro-
inflammatory cytokines could then induce maturation of
CD11c? antigen-presenting cells eventually leading to
MMP expression and permeabilization of the glia limitans.
Thus, the localization of CD11? cells at the glia limitans
provides a possible explanation for their recently described
crucial function in autoimmune neuroinflammation [16]
and raises the possibility that alterations in their recruit-
ment, development, or activation state represents an early
step in the pathogenesis of autoimmune diseases such as
MS.
Our data clearly demonstrate the presence of ramified
cells expressing CD11c and several markers shared with,
but not specific for microglia. The question remains whe-
ther these cells should be regarded as DC. CD11c is a
membrane glycoprotein which belongs to the CD18 family
of integrins, including CD11a, CD11b, and CD11d. Func-
tionally, CD11c is responsible for binding a diverse array
of ligands such as endothelial cell adhesion molecules,
bacterial cell wall components, complement factors such as
iC3b, and matrix proteins [20, 29, 38, 48, 50, 56]. In vivo,
CD11c expression is also induced during early stages of
myeloid cell differentiation [20] and is increased consid-
erably during differentiation of monocytes into tissue
macrophages [50]. CD11c expression is mostly restricted
to cells of the myeloid lineage: macrophages, monocytes,
granulocytes, and at characteristically much higher lev-
els—most DC express CD11c, but a small population of
CD11c? B and T lymphocytes (activated B and cytotoxic
T cells) has also been described [22, 23, 27, 44, 54]. Thus,
the cell type demonstrated herein can either be viewed as a
subpopulation of microglia, which belongs to the mono-
cytic lineage, or might represent a form of immature,
quiescent, or tolerogenic DC which lack the expression of
MHC-II. Beyond pure terminology, the latter would imply
the capability of these cells to carry antigens from the CNS
parenchyma into the draining cervical and lumbar lymph
nodes and other lymphoid organs. Such migration has only
been observed upon injection of DC [9, 17, 21] and seems
to involve the cribriform plate as major exit route from
brain to nasal mucosa [15]. However, at present, direct
evidence for a cell type carrying antigens from the brain to
lymphoid organs is lacking.
Our data unequivocally demonstrate the presence of
CD11c? cells with ramified morphology in the paren-
chyma of normal adult mouse brain, spinal cord and optic
nerve and of a similar population in man. Their extensions
into the glia limitans provide a possible explanation of how
intraparenchymal myelin can be presented to adoptively
transferred T cells. Of note, we found MHC-II expressing
CD11? cells in the choroid plexus, which may be involved
in the previously reported CCR6-dependent recruitment of
Th17 cells into the brain [45]. This route would also be in
line with our observation that CD11c? cells reside in the
ependyma through which T cells could be guided from the
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ventricles. Studying changes in the CD11? population
under neuroinflammatory conditions and subsequently
relating them to MS lesions could provide very useful
information on the development, chronicity, and progres-
sion of MS.
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a r t I C l e S
Multiple sclerosis is a disease of the CNS with largely unknown 
etiology. The symptoms are diverse, but include tremor, fatigue and 
paralysis1. Histopathologically, it presents with large, multifocal 
demyelinated sclerotic plaques scattered throughout the CNS2. These 
lesions are characterized by oligodendrocyte (ODC) death, axonal 
degradation, gliosis, activation of microglia, and perivascular and 
parenchymal accumulation of lymphocytes and macrophages1,2. Such 
inflammatory infiltrates are thought to represent an immune response 
against the CNS, leading to demyelination. However, histopathologi-
cal analyses suggest that neurodegenerative mechanisms could be 
responsible for some aspects of multiple sclerosis, possibly by genetic 
predisposition3. Other studies have even proposed ODC death as the 
first pathological event in the formation of demyelinating plaques4,5. 
ODC death and reactive microglia are present in such ‘early stage’ 
plaques, but blood-derived inflammatory cells are not4,5. Accordingly, 
magnetic resonance imaging studies have found subtle focal changes 
in the white matter weeks before new lesions are formed6,7. Multiple 
sclerosis was therefore proposed to be of neurodegenerative origin, 
with adaptive immune involvement being a secondary phenomenon 
and not a cause. The proposed sequence of events commences with 
autochthonous ODC death, resulting in microglia-macrophage acti-
vation and antigen leakage into CNS-draining lymph nodes (Fig. 1a). 
Myelin-derived antigens presented by danger signal-activated antigen-
presenting cells (APCs) lead to clonal expansion of CNS-reactive 
T cells. These then invade the CNS, amplify myelin damage and lead 
to sustained local inflammation. This model seems to be supported 
by some transgenic mice, in which ODC impairment results in scat-
tered lymphocyte infiltration. However, no actual autoimmunity8,9 is 
found and, in contrast with the observations made in early sclerotic 
plaques4,5, these models do not show substantial ODC death. To test 
ODC death as a trigger of inflammation, we investigated initiation 
of a multiple sclerosis–like pathology in a mouse model (oDTR; 
Supplementary Fig. 1a) in which diphtheria toxin receptor (DTR) 
is expressed specifically in ODCs10 (Supplementary Fig. 1b).
Following injection of diphtheria toxin (DTx), we observed wide-
spread ODC death, extensive myelin damage and accumulation of 
myelin components in CNS-draining lymph nodes. However, even 
after application of immune challenges mimicking pathogenic stimuli, 
we did not induce any anti-self immunity. Thus, ODC death does not 
appear to support development of CNS inflammation even under 
autoimmune-prone experimental conditions.
RESULTS
Motor dysfunction and demyelination following ODC death
To investigate whether ODC death could result in an inflammatory 
disease of the CNS, we generated the oDTR model, in which DTx-
mediated cell ablation was achieved by combining ODC-specific 
Cre recombinase expression (MOGi-cre) with a Cre-inducible DTR 
strain (iDTR)10,11. DTx-induced clinical disease was dose dependent 
with progressive pathology, clinically characterized by exacerbating 
ataxia, tremor, kyphosis and cachexia10. We quantified disease severity 
by weight loss, tremor and motor coordination (see Online Methods 
1Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland. 2Institute for Molecular Medicine, University Medical Center of the Johannes 
Gutenberg, University of Mainz, Mainz, Germany. 3Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Germany. 
4Institute of Pathology, Campus Mitte, Charité – Universitätsmedizin Berlin, Germany. 5Institute of Anatomy, University of Leipzig, Leipzig, Germany. 6Department of 
Neuropathology, Campus Mitte, Charité – Universitätsmedizin Berlin, Germany. 7These authors contributed equally to this work. 8These authors jointly directed this 
work. Correspondence should be addressed to S.W. (woertge@uni-mainz.de) or T.B. (thorsten.Buch@mikrobio.med.tum.de).
Received 11 November 2011; accepted 27 January 2012; published online 26 February 2012; doi:10.1038/nn.3062
Primary oligodendrocyte death does not elicit  
anti-CNS immunity
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Bettina Sobottka1, Martin Krüger5, Khalad Karram2, Claudia Bühlmann1, Ingo Bechmann5, Frank L Heppner6, 
Ari Waisman2,8 & Burkhard Becher1,8
Anti-myelin immunity is commonly thought to drive multiple sclerosis, yet the initial trigger of this autoreactivity remains 
elusive. One of the proposed factors for initiating this disease is the primary death of oligodendrocytes. To specifically test such 
oligodendrocyte death as a trigger for anti-CNS immunity, we inducibly killed oligodendrocytes in an in vivo mouse model. Strong 
microglia-macrophage activation followed oligodendrocyte death, and myelin components in draining lymph nodes made CNS 
antigens available to lymphocytes. However, even conditions favoring autoimmunity—bystander activation, removal of regulatory 
T cells, presence of myelin-reactive T cells and application of demyelinating antibodies—did not result in the development of 
CNS inflammation after oligodendrocyte death. In addition, this lack of reactivity was not mediated by enhanced myelin-specific 
tolerance. Thus, in contrast with previously reported impairments of oligodendrocyte physiology, diffuse oligodendrocyte death 
alone or in conjunction with immune activation does not trigger anti-CNS immunity.
np
g
© 
20
12
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
51
544  VOLUME 15 | NUMBER 4 | APRIL 2012 nature neurOSCIenCe
and Fig. 1b), and observed symptomatic onset around 5–6 weeks post-
administration (p.a.) (Fig. 1b). The mice exhibited rapid decrease 
in motor coordination, resulting in paralysis and ultimately death 
(Fig. 1b and Supplementary Videos 1 and 2). DTx-treated control 
mice showed no signs of disease, confirming the specificity of ODC 
ablation in the oDTR system.
The majority of ODCs in DTx-treated oDTR mice, but not in 
control mice, displayed shrunken nuclei and condensed cytoplasm at 
1 week p.a. (Fig. 1c). Similar to ODCs in early sclerotic plaques4, 
these cells died via a caspase-independent mechanism, as we found 
neither TUNEL+ nor activated caspase-3+ ODCs (data not shown). 
Electron micrographs of DTx-treated oDTR animals revealed dying 
cells with intense vacuolization (Fig. 1d). To quantify ODC loss, 
we stained CNS sections for the ODC-specific protein aspartoacy-
lase (ASPA)4. ODC density in all of the myelin-rich areas decreased 
between 2 and 5 weeks p.a., approaching a 60% cell loss (Fig. 1e and 
Supplementary Figs. 1c and 2a). Major changes in myelin structure 
started to appear at 3 weeks p.a., with obvious vacuolic alterations 
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Figure 1 DTx-treated oDTR mice show ODC death and demyelination. (a) Working hypothesis. (b) Clinical presentation of disease in DTx-treated  
mice. Weight, tremor and motor measurements (mean ± s.e.m.) were combined in one composite score (see Online Methods). (c) Pons from DTx-
treated oDTR mice was stained with Nissl at the indicated time points. Insets, magnified images showing damaged ODCs in oDTR mice. (d) Electron 
micrographs of brainstem revealed normal-appearing ODCs in control mice (left) and moribund ODCs in DTx-treated oDTR mice at 14 d p.a. (right). 
(e) CNS sections from DTx-treated mice were immunostained for ASPA and the numbers of ASPA+ cells were counted. The mean cell density in oDTR 
versus control mice is shown (± s.e.m., n = 3). (f) Spinal cord sections were stained with hematoxylin and eosin (H&E) and Luxol fast blue–periodic 
acid Schiff (LFB-PAS) (6 weeks p.a.) and striatum sections were stained for PLP (4 weeks p.a.). (g) Plp1 and Mag expression in the spinal cords of DTx-
treated mice analyzed by real-time PCR. Shown are the mean values relative to control (± s.e.m., n = 3). (h) MBP- and MOG-specific immunoblotting of 
brain lysates from DTx-treated mice. Shown are mean values ± s.e.m. (n = 3). (i) Electron micrographs of cerebellum revealed normal-appearing axons 
in controls (left) and demyelinated axons (asterisks), vacuoles (arrows) and edematic areas (arrow heads) in DTx-treated oDTR mice (right) 7 weeks p.a. 
(j) Evans blue analysis of spinal cords from DTx-treated mice (1 week p.a.) and from controls (mean ± s.e.m., n = 3). MOG35–55-immunized animals 
showed higher blood-brain barrier permeability. #P < 0.05, ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t test.
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(Fig. 1c,f) coinciding with pronounced demyelination (Fig. 1f and 
Supplementary Fig. 2b). mRNA levels of myelin-associated glyco-
protein (Mag) and proteolipid protein (Plp1) were markedly reduced 
by 1 week p.a. (Fig.  1g), whereas protein levels of myelin oligo-
dendrocyte glycoprotein (MOG) and myelin basic protein (MBP) 
decreased progressively (Fig. 1h). We detected fully demyelinated 
axons starting 5 weeks p.a. (Fig. 1i).
We failed, however, to observe leukocyte infiltration into the lesions 
(Fig. 1f). In addition, we could not detect alterations in the perme-
ability of the blood-brain barrier (Fig. 1j). In conclusion, DTx-treated 
oDTR mice showed massive ODC death, which led to progressive 
demyelination without overt inflammation.
Although widespread ODC death was does not affect the number 
of axons12, it has been shown to lead to strong neuronal loss13. In our 
model, neurofilament-stained CNS sections displayed axonal loss at 
4 weeks after DTx treatment (Fig. 2a). Fluoro-Jade C staining revealed 
widespread damage to neurons (Fig. 2b and Supplementary Fig. 2c) 
and we observed TUNEL+, NeuN+ cerebellar granular layer cells early 
after treatment (Supplementary Fig. 2d). We found accumulation of 
ODC progenitors throughout the CNS starting at 3 weeks p.a. (Fig. 2c), 
and NG2 protein levels were significantly higher in oDTR brains 
than in control brains at 5 weeks p.a. (P = 0.008, ANOVA; Fig. 2d). 
Although oDTR mice succumbed to the DTx-induced ODC loss, 
some remyelination occurred, as shown by g ratio analysis (mean 
g ratio: oDTR, 0.7967 ± 0.0055; control, 0.7536 ± 0.014; P < 0.0001, 
Mann-Whitney test; Fig. 2e).
Antigen drainage from dying ODCs does not prime T cells
The location at which initial antigen presentation and immune acti-
vation in multiple sclerosis occurs remains a matter of debate. In the 
experimental autoimmune encephalomyelitis (EAE) animal model, 
the CNS-draining deep cervical and lumbar lymph nodes provide the 
structural platform for relapse and epitope spreading14, and myelin- 
containing dendritic-like cells are found in these lymph nodes in 
multiple sclerosis15,16. Thus, a spontaneous anti-CNS immune 
response might be initiated in these sites (Fig. 1a). In our model, 
OilRedO (ORO)-stained sections showed a significant lipid increase 
specifically in deep cervical lymph nodes of DTx-treated oDTR mice 
(control, 1.8 ± 0.35 ORO+ cell density; oDTR, 12.4 ± 0.63; P < 0.001, 
Student’s t test; Fig. 3a,b). ORO reactivity represented actual myelin 
antigens, as we also detected increased MBP and MOG levels specifi-
cally in lumbar lymph nodes of DTx-treated oDTR mice (Fig. 3c). 
These data indicate transfer of myelin material exclusively to CNS-
draining lymph nodes following ODC death.
Myelin components in secondary lymphatic tissues should make 
self antigens visible to autoreactive peripheral T cells. To investigate 
this, we injected DTx-treated oDTR mice with carboxyfluorescein 
succinimidyl ester (CFSE)-labeled T cells from the MOG35–55- 
specific, TCR-transgenic mouse strain 2D2 (ref. 17), but observed no 
proliferation of these cells (Fig. 3d). Given that 2D2 T cells recognize 
a rather rare epitope, we increased the amount of cognate antigen by 
crossing oDTR and IiMOG mice, thereby transgenically overexpress-
ing MOG35–55 peptide in ODCs18. Again, we injected CFSE-labeled 
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Figure 2 DTx-induced ODC death leads to sparse neuronal degeneration, recruitment of ODC progenitor and remyelination. (a) oDTR and control mice 
were injected with DTx and killed at the indicated time points. Representative neurofilament-immunostained sections from cerebellum are shown.  
(b) DTx-treated oDTR and control mice were killed at the indicated time points and brain sections were stained with Fluoro-Jade C (FJC). Positively 
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2D2 T cells after induction of ODC death. We also applied pertussis 
toxin (PTx) as an enhancer of CNS inflammation and an agonis-
tic antibody to CD40, which has been shown to increase priming of 
T cells19. Even in this strong pro-inflammatory setting, only 40% of 
the mice showed a minor population of proliferating MOG-specific 
T cells 5 d later, with the majority of the mice displaying no proliferation 
(Fig. 3e). As expected, full T cell proliferation was found in mice that 
ubiquitously expressed MOG35–55 (deleter-cre IiMOG; Fig. 3e)18.
Given that the 2D2 system narrows antigen recognition17, we 
investigated responses to additional myelin antigens. At days 7, 14 
and 30 p.a., cells from lymph nodes were stimulated with PLP, MBP, 
MOG35–55 and ovalbumin (OVA). No increase in proliferation to any 
of these was detected after induced ODC death (Fig. 3f). To exclude 
impairment of T cell priming, we immunized DTx-treated mice with 
keyhole limpet hemagglutinin (a neo-antigen) or MOG35–55 in com-
plete Freund’s adjuvant (CFA). At 9 d post-immunization (p.i.) we 
stimulated cells from lymph nodes with keyhole limpet hemagglutinin 
or MOG35–55 and observed unaltered proliferative responses to the 
antigens following ODC death (Supplementary Fig. 3a). Altogether, 
myelin antigens in CNS-draining lymph nodes failed to initiate anti-
CNS immunity in even the most biased experimental conditions.
Microgliosis, but no T-cell recruitment, following ODC death
Microglia are CNS-resident innate immune cells that constitute 
15% of the total number of parenchymal cells20. Reactive microglia- 
macrophages make up the majority of cells in multiple sclerosis 
plaques21. They have the potential to serve as APCs by expressing 
MHC class I, MHC class II and co-stimulatory molecules22. We found 
that ODC death resulted in an accumulation of CD45int, CD11bhi, 
F4/80+, Iba1+ activated microglia-macrophages starting 1 week p.a. 
(Fig. 4a,b and Supplementary Fig. 1c). These cells appeared to be 
morphologically reactive (Fig. 4c) and showed upregulation of MHC 
class II and CD44 (Fig. 4d,e). Similarly, we detected progressive astro-
gliosis by staining for glial fibrillary acidic protein (GFAP; Fig. 4f and 
Supplementary Fig. 1c). However, the CNS of DTx-treated oDTR mice 
was devoid of B and T lymphocytes, as shown by histology and flow 
cytometry (Fig. 4g and Supplementary Fig. 3b). Thus, DTx-induced 
ODC death led to marked micro- and astroglia activation without 
adaptive immune involvement.
To better mimic multiple sclerosis as a progressive disease with 
sparse focal demyelination, we tested a strategy of chronic, albeit lim-
ited, ODC death. We treated oDTR mice with a low weekly dose of DTx 
(50 ng, intraperitoneal) for 5 months, leading to mild demyelination, 
sparse ODC death (Fig. 5a,b) and increased numbers of Iba1+ microglia- 
macrophages (Fig.  5c) in the absence of a clinical phenotype 
(data not shown). Again, the percentages of blood leukocytes did 
not vary between DTx-treated oDTR and control mice (in blood, 
7 and 15 weeks p.a., data not shown; in the CNS, 19 weeks p.a.; 
Fig. 5d), and cells from the lymph nodes failed to proliferate in 
response to MOG, PLP, MBP, MOG35–55 and total brain homogenate 
(data not shown). Thus, even chronic ODC death did not result in 
an anti-CNS adaptive immune response.
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Figure 3 Rare activation of T cells following myelin antigen leakage.  
(a) Sections from deep cervical lymph nodes of DTx-treated oDTR  
mice were ORO-stained 3 weeks p.a. Arrow indicates representative  
ORO+ cells. (b) Quantification of ORO+ cells in lymph nodes of  
DTx-treated mice at 3 weeks p.a. (mean ± s.e.m., n = 4).(c) MBP-,  
MOG- and Vinculin (Vinc)-specific immunoblotting of CNS-draining  
lymph nodes from DTx-treated oDTR and control mice at 1 and 2 weeks p.a. CNS lysate was used as a positive control. Arrows indicate expected 
molecular weights. (d) We injected 107 CFSE-labeled CD90.1+ 2D2 T cells into DTx-treated CD90.2+ mice 1, 2 and 3 weeks p.a. and analyzed them 4 d  
later. As additional controls, we used B6 mice that were either untreated (bottom center and right) or MOG35–55-immunized (bottom left). (e) CD90.2
+ 
B6 mice received daily injections of DTx (25 ng per g of body weight) from day −3 to day 0. CFSE-labeled 2D2 cells (CD90.1+, day 0), PTx (day 0 and 
2) and antibody to CD40 (30 µg, day 5) were applied. We analyzed cells from lymph nodes by flow cytometry 5 d after transfer. We used deleter-cre 
IiMOG mice as a positive control. (f) Cells were isolated from peripheral and CNS-draining lymph nodes of DTx-treated oDTR mice at 7, 14 and 30 d p.a 
and stimulated in culture with OVA, PLP, MBP and MOG35–55 (with or without antibody to CD28). MOG35–55-immunized mice, 9 days p.i., served as a 
positive control. Shown are mean ± s.e.m., n = 4. ***P < 0.001, Student’s t test. 
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EAE incidence. However, a similar fraction of mice developed EAE symp-
toms in both groups (6 of 18 oDTR-2D2 mice, 4 of 17 control mice), with 
comparable onset and severity (Fig. 5g). We then activated APCs by injec-
tion of agonistic CD40-specific antibodies19 after inducing ODC death. 
We found clear hyper-activation of microglia-macrophages (Fig. 5h and 
Supplementary Fig. 4c) and astroglia (Supplementary Fig. 4b) in the 
CNS of oDTR mice that received both treatments. In addition, these mice 
displayed a slight reduction in ODC density compared with oDTR mice 
that were only treated with DTx (Supplementary Fig. 4a). Nevertheless, 
we observed no clinical difference between the groups (Fig. 5i) and no 
accumulation of lymphocytes in the demyelinated CNS (data not shown). 
Thus, no specific lymphocyte response followed ODC death in presence 
of strong immune activation.
Absence of CNS inflammation is not a result of T cell tolerance
Accumulation of antigen in the context of a non-inflamed environ-
ment usually leads to T cell tolerance by deletion, anergy or suppres-
sion28. To determine whether such tolerance prohibits an anti-myelin 
Figure 4 Activation of microglia-macrophages, 
but no inflammation following ODC death. 
(a) Flow cytometric analysis of cells isolated 
from the CNS of DTx-treated mice. Shown are 
percentages for invading cells (CD45hi CD11b−), 
macrophages (CD45hi CD11bhi) and microglia 
(CD45int CD11bhi). Data are representative  
of two independent experiments (n = 6).  
(b) CNS sections from DTx-treated oDTR and 
control mice were immunostained for Iba1  
and Iba1-positive cells were quantified. The 
mean cell density in oDTR versus control  
mice is shown (± s.e.m., n = 3).(c) Iba1-
immunostaining of brain sections from  
DTx-treated oDTR mice, 5 weeks p.a.  
(d) Brain sections of DTx-treated mice showing 
MHCII+ microglia-macrophages 4 weeks p.a. 
(e) Flow cytometric analysis of cells isolated 
from the CNS of DTx-treated mice. Shown 
are percentages of CD45int CD11bhi CD44+ 
microglia (mean ± s.e.m., n = 3).  
(f) CNS sections from DTx-treated mice were 
immunostained for GFAP and positive cells were 
counted. The mean cell density in oDTR versus 
control mice is shown (±s.e.m., n = 3). (g) CNS 
of DTx-treated mice (400 ng DTx at day 0, 2,  
4 and 6) was analyzed by flow cytometry 50 d p.a. 
Absolute numbers of infiltrating T cells are 
shown, data representative of two independent 
experiments (mean ± s.e.m., n = 5). Cells from 
the CNS of MOG35–55-immunized (mean ± s.e.m., 
n = 3) and untreated mice (B6, mean ± s.e.m.,  
n = 4) served as controls. *P < 0.05,  
**P < 0.01, ***P < 0.001, Student’s t test. 
1 week p.a. 6 weeks p.a.
Control
a
b
c
e gf
d
Control
CD11b
3.5
** **
**
*
*
**
** ** **
**
***
*** ***
**
**
**
** **
*
*
*
***** ******
**
******3.0
2.5
2.0
1.5
1.0
0.5
0
3.5
3.0
3.0
2.5
2.5
2.0
2.0
1.5
1.5
1.0
1.0
0.5 0.5
0 0
70 10
9
16
3.0
2.5
2.0
1.5
1.0
0.5
0
3.0
2.5
2.5
2.0
2.0
1.5
1.5
1.0
1.0
0.5 0.5
0 0
2.5
2.0
1.5
1.0
0.5
0
2.5
2.0
1.5
1.0
0.5
0
1 2 3 4 7 1 2 3 4 7
1 2 3 4 7
Cerebellum Corpus callosum Brainstem Cortex
Weeks p.a.
oDTR 5 weeks
Un
tre
at
ed B6
oDTR
1 2 3 4 7
Weeks p.a.
Control
50 µm 200 µmTomato lectin
MHC class II
Tomato lectin
MHC class II
1 2 3 4 7
Weeks p.a.
Weeks p.a.
1 2 3 4 7
Weeks p.a.
1 2 3 4 7
Weeks p.a.
Cortex Brainstem
Weeks p.a.
Cerebellum Corpus callosum
1 2 3 4 7
Weeks p.a.
0.3
C
D
45
oD
T
R
/c
on
tr
ol
ce
lls
 ×
 0
.2
5 
m
m
2
oD
T
R
/c
on
tr
ol
ce
lls
 ×
 0
.2
5 
m
m
2
oD
T
R
/c
on
tr
ol
ce
lls
 ×
 0
.2
5 
m
m
2
C
el
ls
 p
er
 C
N
S
(×
 1
03
)
C
el
ls
 p
er
 C
N
S
(×
 1
03
)
P
er
ce
nt
ag
e 
of
C
D
44
+
 m
ic
ro
gl
ia
CD4+ T cells
CD8+ T cells
0.3 1.1 4.2 0.4 1.9 3.4 5.9
253.56.63.3
oDTR oDTR
60
50
40
30
20
10
0
8
7
6
5
3
1
4
2
0
14
12
10
8
6
4
2
0
oD
TR
Co
nt
ro
l
EA
E
oD
TR
Co
nt
ro
l
EA
E
B6
oD
TR
Co
nt
ro
l
EA
E
rosis is the presence of oligoclonal bands (immunoglobulins) and 
plasma cells in the cerebrospinal fluid23,24. CNS-infiltrating B cell 
clones produce autoantibodies25 that damage and opsonize myelin 
membranes. We previously found that antibody to MOG increases 
clinical disease in the EAE model26; we therefore investigated whether 
a similar effect could be achieved in the oDTR model. We first con-
firmed that radio-labeled antibody to MOG accumulated in the 
CNS of DTx-treated oDTR mice (Fig. 5e). However, we observed no 
clinical differences between antibody to MOG administration and 
antibody to nitrophenyl-hapten administration following ODC death 
(Fig. 5f). Histologically, application of antibody to MOG resulted 
in increased ODC loss and stronger glial activation compared with 
the control group, which received antibody to nitrophenyl-hapten 
(Supplementary Fig. 4a–c). However, we observed no lymphocytic 
infiltrates in CNS sections stained with hematoxylin and eosin and 
antibody to CD3 (data not shown). Thus, the application of anti-
body to myelin did not aid the development of anti-CNS immunity 
in oDTR mice.
For activation, auto-reactive T cells must encounter licensed APCs27. To 
combine demyelination with immune activation, we treated oDTR and 
control mice with PTx and CFA after DTx application, but failed to observe 
CNS inflammation (data not shown). For further enhancement of potential 
immunity against the CNS, we crossed oDTR and control mice with 2D2 
mice. The latter display a low incidence of spontaneous EAE, which can 
be markedly augmented by the administration of adjuvants17. We treated 
oDTR-2D2 and control mice with DTx and with CFA-PTx to increase 
Experimental triggers of inflammation 
following ODC death
One important hallmark of multiple scle-
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response in the oDTR model, we tested whether ODC death interfered 
with EAE development. oDTR mice and controls were treated with 
DTx or BSA and immunized with MOG35–55 in CFA, with or without 
PTx. The resulting clinical pathology (Fig. 6a) and disease incidence 
(Table 1) were comparable in all of the mice. A similar number of 
equally activated inflammatory infiltrates were found at disease onset 
by flow cytometry (data not shown). Thus, we found no indication of 
tolerance induction after ODC death. To further exclude tolerance, 
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Figure 5 Chronicity, demyelinating antibodies or immune activation do not induce autoimmunity following ODC death. (a) Representative LFB-PAS–
stained sections from brainstems of mice treated with DTx (50 ng weekly) for 5 months. (b) Representative Nissl-stained sections from pons of DTx-
treated mice (50 ng), 3 d p.a. Magnifications show damaged ODCs in oDTR mice. (c) We treated mice as described in a and immunostained cerebellar 
sections for Iba1. (d) Flow cytometric analysis of cells isolated from the CNS of mice treated as described in a. Shown are the mean percentages of total 
CD4+ and CD8+ (CD11b− CD45hi) and effector lymphocytes (CD44hi CD62Llow CD4+ and CD44hi CD62L lowCD8+) ± s.e.m. (n = 6). (e) DTx-treated mice 
were injected with 125I-labeled antibody to MOG 4 weeks p.a. After 12 h, we analyzed the CNS for radioactive incorporation with a gamma counter (n = 2).  
(f) oDTR and control mice were treated as described in Figure 4g and were intravenously administered 200 µg of MOG-specific or nitrophenyl-hapten 
(NP) specific antibody at day 14, 21 and 28. Composite clinical score is shown. (g) Disease course of DTx-treated mice (three times, 25 ng per g) 
injected with CFA (day 0) and PTx (day 0 and 2) 7 d p.a. Data were pooled from three independent experiments (n = 32). (h) Mice were treated with 
250 ng of DTx weekly and two mice per group received 200 µg of CD40-specific antibody on day 30, 37 and 44 p.a. Corpus callosum sections were 
immunostained for Iba1 55 d p.a. (i) oDTR and control mice were treated as described in h, and composite clinical score is shown.
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Figure 6 ODC death does not result in increased 
tolerance toward myelin. (a) oDTR mice were 
treated with DTx or BSA and immunized with 
MOG35–55 in CFA at day 0. PTx was injected at 
day 0 and 2. Mice were scored as described in 
the Online Methods. Data are representative of 
two independent experiments (n = 8). Shown 
are mean values ± s.e.m. (b) oDTR IiMOG mice 
and MOGi-cre IiMOG controls were treated for 
tolerance induction as described in scheme. 
Lymph node cells were analyzed by flow 
cytometry. Shown are cells gated on CD4+ cells. 
The percentages of cells lying in the CD90.1+ 
CD4+ and CD90.1− CD4+ gates are indicated.  
(c) DTx-treated oDTR and control mice were 
injected at day 1, 3 and 5 with 150 µg of CD25-
specific antibody or IgG isotype control. On day 8, 
blood was collected, stained for CD45, CD4, CD25 
and Foxp3 and analyzed by flow cytometry. Bar 
graph shows mean percentages ± s.e.m. of Foxp3+ 
CD25+ cells in the CD4+ population (n = 9).  
***P < 0.001, Student’s t test. (d) oDTR and  
control mice were treated as described in c. Compo-
site clinical score is shown. Data representative  
of two independent experiments (n = 10).
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we injected CD90.2+ oDTR-IiMOG and MOGi-cre IiMOG control 
mice with 107 CD90.1+ CFSE-labeled T cells from 2D2 mice after 
inducing ODC death. We tolerized half of the mice from both groups 
1 d after cell transfer by injection of MOG35–55 in phosphate-buffered 
saline (PBS), and then immunized the mice on day 6 with MOG35–55 
in CFA. Tolerized mice had a reduced number of CD90.1+ proliferat-
ing lymphocytes compared with untolerized mice (Fig. 6b); such a 
reduction was not achieved through DTx application in oDTR mice. 
Thus, MOG protein released from dying ODCs did not induce toler-
ance to MOG35–55.
We also ablated regulatory T cells29, which have been shown to 
display defective suppressive activity in multiple sclerosis. We injected 
DTx-treated mice with antibody to CD25 (PC61)29 or isotype control 
antibodies and observed a significant reduction in the number of 
CD4+, CD25+, Foxp3+ cells in the blood of mice treated with antibody 
to CD25 (P < 0.001, Student’s t test; Fig. 6c). No substantial difference 
in clinical disease was found between DTx-treated mice injected with 
CD25-specific or isotype control antibody (Fig. 6d). However, we 
detected stronger activation of microglia and astroglia in mice treated 
with antibody to CD25 compared with oDTR mice that were only 
treated with DTx (Supplementary Fig. 4b,c), probably an indirect 
result of systemic immune de-regulation. Again, neither hematoxy-
lin and eosin– nor antibody to CD3–stained sections revealed lym-
phocyte accumulation in the diseased CNS (data not shown). To test 
whether ablation of regulatory T cells led to subclinical activation of 
myelin-specific T cells, we stimulated lymph node cells in vitro with 
major myelin proteins, but failed to detect any specific response (data 
not shown). Taken together, these findings indicate that tolerance was 
not induced by antigen released by dying ODCs.
DISCUSSION
Multiple sclerosis is generally accepted to be an autoimmune dis-
ease with autoreactive T cells driving multifocal and heterogeneous 
inflammatory demyelination. However, some findings suggest that the 
observed histological subtypes3 correspond to various stages along 
the disease course4, with primary apoptosis of ODCs as a common 
triggering event. To test this notion, we designed a mouse model 
in which DTR-expressing ODCs are killed by application of DTx10. 
In contrast with other models of demyelination, the mechanism of 
DTx-induced death is well established30 and is restricted to mature 
ODCs10. This is not the case for the cuprizone system, where the 
mode of action is unknown and impairment of liver metabolism and 
inhibition of T cell functions have been reported31,32. In addition, 
two other, almost identical, mouse models of ODC depletion show 
no lymphocyte infiltrations in the CNS12,13, but use tamoxifen, a well-
established suppressor of autoimmunity, as an inducer33.
In our model, we observed widespread ODC death and progressive 
demyelination with clinical signs such as cachexia, ataxia, kyphosis 
and tremor. The latter can result from the degeneration of neurons 
observed in the cerebellum of treated mice8,34. In addition, we found 
progressive gliosis and activation of microglia-macrophages with high 
expression of MHC class II and CD44 (refs. 35,36), similar to other 
models of myelin damage37–39 and to microglia reactivity in early 
stage sclerotic plaques4,40.
As is also observed in multiple sclerosis studies15,16, ODC death 
in oDTR mice resulted in accumulation of myelin material in 
CNS-draining lymph nodes, candidate locations for activation of 
CNS-reactive lymphocytes14. Nonetheless, following both acute 
and chronic DTx-mediated ODC death, we did not detect any T cell 
activation nor parenchymal or perivascular lymphocyte infiltrations 
into the CNS.
To test bystander activation as a potential mechanism, we induced 
ODC death in conjunction with established triggers and enhanc-
ers of inflammation, such as CFA, PTx, transgenic MOG-reactive 
T cells, depletion of regulatory T cells, demyelinating antibodies and 
treatment with antibody to CD40. Despite these strong experimental 
triggers of T cell activation and inflammation, we observed neither 
signs of anti-CNS immunity nor changes in disease compared with 
control mice. We also excluded the possibility that induced tolerance 
precluded development of anti-CNS immunity, as has been described 
for other demyelinating procedures41.
Although we detected rare stochastic activation of adaptive immu-
nity (Fig. 3e), our endeavor to detect lymphocytic inflammation after 
primary ODC damage clearly failed. In particular, even following 
employment of the most biased experimental approaches to favor 
anti-CNS immunity, we could not elicit inflammation that was even 
remotely comparable to that elicited in EAE or multiple sclerosis.
Previous studies have linked pathologically modified ODCs with 
severe neural degeneration in the absence of inflammation42–44. In 
other procedures, such as ODC-restricted deletion of Pex5 (ref. 8) 
and overexpression of PLP9, neuronal death and scattered lymphocyte 
infiltration in the CNS are observed. Given that ODC survival is not 
affected in these models, it is possible that compromised ODCs signal 
their distress to the immune system and thus recruit lymphocytes. 
Our data, on the other hand, support the notion that ODC death 
per se does not represent a stimulus for adaptive immunity. In another 
disease entity, X-linked adrenoleukodystrophy, ODC death and 
inflammation have been observed45, but it remains unclear whether 
this inflammation is the cause or the result of the characteristic demye-
linating processes.
Taken together, we addressed a neurodegenerative hypothesis for 
multiple sclerosis pathogenesis and we excluded a large number of 
pathological factors leading up to autoimmune conditions. Even 
though DTx-treated oDTR mice displayed histopathological changes 
that closely resemble lymphocyte-free early stage multiple sclerosis 
lesions, our insult to the CNS did not lead to the inflammation that is 
commonly described in late-stage multiple sclerosis plaques3 and other 
neuroinflammatory diseases. Thus, assuming that a human disease 
such as multiple sclerosis can be modeled in animals, our findings sug-
gest that ODC death is not sufficient to trigger CNS inflammation.
METHODS
Methods and any associated references are available in the online 
version of the paper at http://www.nature.com/natureneuroscience/.
Note: Supplementary information is available on the Nature Neuroscience website.
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ONLINE METHODS
Animal maintenance and genotyping. The animals were kept under specific 
pathogen free and optimized hygienic conditions according to Swiss and German 
animal law and institutional guidelines. Typing primer pairs are: MOGi-cre 
(wild type, 350 bp) GACAATTCAGAGTGATAGGACCAGGGTATCCC and 
GCTGCCTATTATTGGTAAGAGTGG; MOGi-cre (knock-in, 700 bp) 
TCCAATTTACTGACCGTACAC and CATCAGCTACACCAGAGACGGAA 
ATC; iDTR (wild type, 600 bp; knock-in, 845 bp) AAAGTCGCTCTGAGTTGTTAT, 
GGAGCGGGAGAAATGGATATG and AATAGGAACTTCGTCGAGC; IiMOG 
(wild type, 456 bp; knock-in, 982 bp) GGCTACTGCTGACTCTCAACATT, 
ATTTCGGTAGAGGTGAACCACGGCTACTGCTGACTCTCAACATT, 
ATTTCGGTAGAGGTGAACCACTC and CAGGGTTTCCTTGATGATGGTT
TCCTTGATGATGTC; deleter-cre (600 bp) GAAAGTCGAGTAGGCGTGTACG 
and CGCATAACCAGTGAAACAGCAT.
disease  models. EAE was induced in 8–10-week-old mice as previously 
described46. Unless otherwise specified, ODCs were ablated by 200 ng DTx 
(Merck) intraperitoneally daily over 7 d. We used antibodies to CD40 (FGK4.5, 
BioXcell), CD25 (PC61, BioXcell) and MOG (818C5). In RotaRod experiments, 
the average time to fall was measured during a 5–50 rpm acceleration over 
3 min (n = 3). In the walking grid assay (Supplementary Video 1), we counted 
the number of footfalls over a 50-cm-long runway with irregularly arranged bars 
(0.5–2.5 cm) on a 10-cm distance, fixing maximum errors to 10. Tremor was 
measured on a scale from 0–3, with 0 indicating absence of tremor, 1 indicating 
low tremor during motor tests, 2 indicating strong tremor during motor tests and 
low tremor in cage, and 3 indicating strong tremor during motor tests and in cage. 
For the composite score, each measurement was first re-calculated into percent-
ages, assuming the weight and RotaRod score measured before DTx administra-
tion, a grid walking test without errors, and absence of tremor as 100%.
cell  culture  and  flow  cytometry. For in vivo proliferation experiments 
lymph node and spleen cells were purified with CD4 microbeads (Miltenyi 
Biotech) after erythrocyte lysis (BD Biosciences). Cells were CFSE labeled as 
described previously47.
Flow cytometry analysis was performed as previously described48,49. We pur-
chased 53-6.7 (CD8), N418 (CD11c), H57 (TCRβ), 7AD/PC61 (CD25), IM7 
(CD44), 30-F11 (CD45), MEL-14 (CD62L), M1/70 (CD11b) and M5/114 (MHC-II) 
antibodies from BD Biosciences, RM4-5 (CD4) antibody from Biolegend, and 
BM8 (F4/80) and FJK-16s (Foxp3) antibodies from eBioscience. Dead cells were 
excluded by LIVE/DEAD staining (Invitrogen), Topro-3 (10 nM, Invitrogen) 
or propidium iodide (0.2 mg ml−1, Sigma-Aldrich). Analyses were performed 
on a FACSCantoII (BD) and analyzed by FlowJo software. For radioactive pro-
liferation assays, we activated 2 × 105 lymph node cells per well with 60 µg ml−1 
MOG35–55 (Genscript), 20 µg ml−1 PLP protein (AbDserotec), 20 µg ml−1 MBP 
protein (Chemicon international), 10 µg ml−1 concanavalin A (Sigma-Aldrich), 
5 µg ml−1 antibody to CD3e (2C11, BioXcell) or 5 µg ml−1 antibody to CD28 
(37N, Bioexpress) in complete IMDM in a 96-well plate (in quadruplicates).
Histology. For cryosections, tissues were embedded (Mdite), frozen (dry ice), 
cut sagittally at 10 µm and thaw-mounted onto glass slides (Menzel GmbH). 
Sections were air-dried overnight, fixed with 4% paraformaldehyde (PFA, 
wt/vol, AppliChem, 10 min) and washed three times with PBS. TUNEL 
staining was performed with In situ Cell Death Detection Kit (Roche). For 
vibratome sections, tissues were fixed overnight (4% PFA), cut sagittally at 
40 µm and stained50 with antibody to GFAP (DAKO), ASPA (rabbit polyclo-
nal serum, M. Klugmann, University of New South Wales), PLP (rat, home-
made), F4/80 (rat, homemade), NG2 (rat monoclonal, J. Trotter, Johannes 
Gutenbergh University of Mainz) or Iba1 (rabbit, Wako). For detection, we 
used horseradish peroxidase–conjugated antibodies (Vector Laboratories) or 
3,3-diaminobenzidine (DAB, Sigma-Aldrich). MHC–II–specific antibody (rat, 
BD Biosciences) and tomato lectin (Sigma-Aldrich) were used for immuno-
fluorescence. Secondary antibodies were labeled with Cy3 or FITC (Dianova). 
For paraffin sections, CNS was perfused, fixed (4% PFA in PBS) and after 
paraffin-embedding cut at 5 µm. Hematoxylin and eosin and LFB-PAS staining 
were performed according to standard protocols. Myelin lipids were detected with 
0.3% OilRedO (wt/vol, Gurr) in 60% 2-propanol (vol/vol) and counterstained 
with hematoxylin. Iba1 (rabbit, Wako) and CD3 (Thermo Scientific) staining 
was performed by a Ventana Benchmark XT-automated staining according 
to the manufacturer’s guidelines. For neurofilament staining (Millipore), sec-
tions were dewaxed, dehydrated, antigen retrieved in citrate buffer (pH 6.0) 
for 10 min after incubation in 0.3% hydrogen peroxide blocked with 3% nor-
mal goat serum (vol/vol) and 0.3% Triton X-100 (vol/vol) in PBS and stained 
(12 h at 21 °C). A biotinylated antibody (Vector) was used for detection, and DAB 
was developed using the Vectastatin ABC kit (Vector). Sections were counter-
stained for 2 min (hemalaun, Dr. Hollborn and Sons).
Transmission  electron microscopy. After perfusion with PBS followed by 
1% glutaraldehyde (vol/vol), 2% PFA and 0.2% picric acid (vol/vol) in 0.1 M 
phosphate buffer, pH 7.4, the tissue was post-fixated in 2.5% glutaraldehyde 
followed by 2% osmium tetroxide (vol/vol) in PBS for 2 h. Samples were dehydrated 
using a Leica EM TP (Leica) and embedded in Epon at 60 °C for 48 h. We stained 
70-nm ultra-thin sections with 4% uranylacetate and lead citrate (vol/vol). 
Samples were visualized using a Phillips CM 100 transmission electron micro-
scope (FEI) with a Gatan 4,000 × 3,000 camera (Gatan).
Iodine labeling of 818c5 and radioactivity detection. Na125I (629 GBq mg−1, 
PerkinElmer) was activated in pre-coated iodination tubes (Thermo Scientific) 
and mixed with MOG-specific antibodies. The reaction was stopped with a satu-
rated solution of tyrosine (10 mg ml−1) and antibody purified through a 10-ml 
polyacrylamide desalting column (Thermo Scientific). Antibody-containing frac-
tions were pooled. We killed and perfused the mice 12 h after 125I-818C5 injec-
tion, and analyzed their CNS in a Kontron Gammamatic (Sertec Electronics).
Immunoblotting. Mouse tissues were lysed (35 mM Tris-Cl, 150 mM NaCl, 
1% NP-40, 0.5% sodium deoxycholate, 1% Triton X-100, 1 mM Na3VO4, 1 µg ml−1 
leuptinin, 5 mM NaF and 5 mM PMSF) for 30 min, sonicated and centrifuged at 
16,046g at 4 °C for 20 min. After BCA assay (Thermo Scientific), proteins were 
blotted and detected with antibodies to Vinculin (Cell Signaling), MOG (818C5), 
MBP (Santa Cruz) and NG2 (Millipore). Samples for NG2 immunoblotting were 
digested with Chondroitinase ABC (Seikagaku) for 1 h at 37 °C. In Figure 3c, 
160 µg of lysate from lymph nodes and 80 µg lysates from CNS were loaded.
evans blue extravasation. Animals were injected intraperitoneally with Evans 
Blue (0.5 ml of 0.8% in PBS). After 24 h, we perfused the mice and isolated, 
weighted and homogenized the CNS in 1 ml of 3.05 N trichloracetic acid. After 
centrifugation, Evans Blue was excited at 620-nm and recorded at 680-nm wave-
length in an Infinite M1000 microplate reader (Tecan).
Statistical analysis. Statistical analysis of RT-PCR, in vitro proliferation assays, 
cell density by histology and cell percentages by flow cytometry were performed 
by two-tailed Student’s t test. Evans Blue and quantification of bands from 
immunoblotting were analyzed by ANOVA and post hoc Tukey’s test. Analysis 
of g ratio was performed by Mann-Whitney test.
46. Haak, S. et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-
inflammation in mice. J. Clin. Invest. 119, 61–69 (2009).
47. Weston, S.A. & Parish, C.R. New fluorescent dyes for lymphocyte migration studies. 
Analysis by flow cytometry and fluorescence microscopy. J. Immunol. Methods 133, 
87–97 (1990).
48. Becher, B., Durell, B.G. & Noelle, R.J. Experimental autoimmune encephalitis and 
inflammation in the absence of interleukin-12. J. Clin. Invest. 110, 493–497 
(2002).
49. Förster, I. & Rajewsky, K. Expansion and functional activity of Ly-1 + B cells upon 
transfer of peritoneal cells into allotype-congenic, newborn mice. Eur. J. Immunol. 17, 
521–528 (1987).
50. Spergel, D.J., Kruth, U., Hanley, D.F., Sprengel, R. & Seeburg, P.H. GABA- and 
glutamate-activated channels in green fluorescent protein-tagged gonadotropin-
releasing hormone neurons in transgenic mice. J. Neurosci. 19, 2037–2050 
(1999).
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Summary 
The term blood-brain barrier (BBB) relates to the ability of cerebral vessels to hold back 
hydrophilic and large molecules from entering the brain, thereby crucially contributing to 
brain homeostasis. In fact, experimentally opening of endothelial tight junctions causes a 
breakdown of the BBB (evidenced, e.g., by a leakage of albumin) and the generation of 
epileptiform activities. This and similar observations led to the conclusion that BBB 
breakdown is always caused by damage to tight junction complexes, but evidentiary 
ultrastructural data are rare. Since functional deficits of the BBB are crucially contributing to 
the risk of hemorrhagic transformation and brain edema after stroke, which both critically 
impact on the clinical outcome, we studied the mechanism of BBB breakdown by using an 
embolic model of focal cerebral ischemia in Wistar rats which closely mimics the essential 
human pathophysiology. Ischemia-induced BBB breakdown was detected using intravenous 
injection of FITC-albumin and tight junctions in areas of FITC-albumin extravasation were 
subsequently studied using fluorescence and electron microscopy. Against our expectation, 25 
hours after ischemia induction the morphology of tight junction complexes (identified 
ultrastructurally and using antibodies against the transcellular proteins occludin and claudin-
5) appeared to be regularly maintained in regions where FITC-albumin massively leaked into 
the neuropil. Occludin signals along pan-laminin-labeled vessels in the affected hemisphere 
equaled the non-affected contralateral side (ratio: 0.966 versus 0.963; P=0.500). At the 
ultrastructural level, FITC-albumin was clearly found to penetrate vessels with intact tight 
junctions, but the endothelium exhibited enhanced transendothelial vesicle trafficking and 
signs of degeneration. Thus, BBB breakdown and leakage of blood-derived albumin into the 
brain’s parenchyma is not caused by degradation of tight junctional proteins at least until one 
day after experimental embolic stroke. Understanding the mechanisms causing functional 
endothelial alterations and endothelial damage is likely to provide novel protective targets in 
stroke. 
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Introduction 
Ischemic stroke still represents one of the leading causes of death worldwide (Donnan et al., 
2008). On the cellular level, the ischemia-induced breakdown of the blood-brain barrier 
(BBB), which is known to contribute to an increased risk of hemorrhagic transformation and 
brain edema with perilous outcome, was often linked to a putative disruption of tight junctions 
in the endothelial layer of cerebral vessels (Sandoval and Witt, 2008). However, this putative 
mechanism of breakdown has never been convincingly proven by ultrastructural analyses in 
conjunction with physiological conditions.  
Originally, the observation that cerebral vessels hold back hydrophilic molecules from 
entering the brain was first described by Paul Ehrlich in 1885 (Ehrlich, 1885). In 1900, Max 
Lewandowski drew the revolutionary conclusion that the morphological correlate of this 
barrier function indeed must be the capillary wall (Lewandowski, 1900). However, it was not 
clear which properties rendered the cerebral vessels outstanding in regard to their barrier 
function compared to the vasculature of peripheral organs. It was the groundbreaking paper 
by Reese and Karnovsky (1967) to link this function with belts of endothelial tight junctions 
in cerebral capillaries. These complexes consist of three major transmembrane protein 
families comprising occludin, claudins and junction associated proteins (JAMs), as well as 
several cytoplasmic proteins including the zonula occludens (ZO) protein family consisting of 
ZO-1, ZO-2 and ZO-3. The latter readily link the proteins to the actin cytoskeleton (Wolburg 
and Lippold, 2002; Sandoval and Witt, 2008). Whereas this general composition is also 
known for epithelial tight junctions of peripheral organs, some proteins were found to be 
specific for brain endothelial cells, such as cingulin, claudin-3 and -5, while other epithelial 
components are lacking in the vasculature of the central nervous system (Liebner et al., 2000; 
Hawkins and Davis, 2005). However, conclusive data proving the functional relevance of 
these constituents in establishing the special features of cerebral vessels are still lacking.  
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Under physiological conditions cerebral endothelial cells ensure the outstanding 
cerebral barrier function, which is maintained by the critical interaction of pericytes, 
astrocytes, neurons and the extracellular matrix as parts of the neurovascular unit (NVU) 
(Zlokovic, 2008). In this context, astrocytes were originally thought to induce BBB 
characteristics in cerebral endothelial cells (Stewart et al., 1981; Arthur et al., 1987; Janzer 
and Raff, 1987; Bell et al., 2012), but also pericytes were shown to enhance their barrier 
function (Dente et al., 2001; Winkler et al., 2011). In the concert of cells constituting the 
NVU the establishment and maintenance of the BBB represents a permanently regulated 
process which begins in early development and lasts throughout ageing (Armulik et al., 2010; 
Bell et al., 2010; Daneman et al., 2010). The criticial impact of proper endothelial function is 
exemplarily demonstrated by experimental disruption of endothelial tight junctions, which 
resulted in generation of epileptiform activity by failure of cellular homeostasis in the NVU 
(Seiffert et al., 2004) 
During ischemic stroke alterations in cerebral blood flow by acute vessel occlusion 
result in energy failure of the NVU, thereby causing mitochondrial damage, release of toxic 
oxygen species and intracellular edema (Dirnagl et al., 1999; Mergenthaler et al., 2004; 
Endres et al., 2009; del Zoppo, 2010; Tarawneh and Galvin, 2010). Furthermore, upregulation 
of the matrix metalloproteinases MMP-2 and -9, as well as of the vascular endothelial growth 
factor (VEGF) are closely associated with BBB disruption (Yang et al., 2007; Bauer et al., 
2010). In the past, this event was often exclusively linked to tight junction failure 
consequently leading to an extravasation of blood-borne molecules along the paracellular 
route (Mark and Davis, 2002; Sandoval and Witt, 2008, Jiao et al., 2011). Indeed, a variety of 
studies reported on alterations in the expression or localization of critical tight junction 
proteins, such as occludin, claudin-5 and ZO-1 in diverse models of in vitro hypoxia as well 
as of global and focal cerebral ischemia in rodents (e.g., Fischer et al., 2000; Mark and Davis, 
2002; McCaffrey et al., 2009; Bauer et al., 2010; Jiao et al., 2011). However, no conclusive 
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concept of BBB breakdown during ischemia can be drawn from these studies. Moreover, 
tracers used to visualize BBB leakage have been reported to produce artifacts. Examples are 
Evans blue (Jiang et al., 2007; Qin et al., 2007; Yang et al., 2007; Liu et al., 2008; Wang et 
al., 2009; Zhao et al., 2010) or fluorescein-labeled dextrans (Nagaraja et al., 2008; Chen et 
al., 2009; Kisucka et al., 2009). This issue might substantially contribute to the present 
situation: In contrast to the well-known clinical impact of the BBB integrity during stroke, the 
respective regulatory processes are poorly understood, most likely impeding therapeutic 
interventions (Meairs et al., 2006; Endres et al., 2008). Furthermore, with regard to the 
translational failure of more than 1,000 neuroprotective approaches in stroke (O’Collins et al., 
2006) a discussion came up concerning the comparability of frequently applied rodent 
models, based on their preponderant artificial techniques for vessel occlusion such as 
electrocauterization or filament insertion (Young et al., 2007; Fisher et al., 2009).  
The present study aimed at the ultrastructural analysis of tight junction integrity in an 
embolic model for middle cerebral artery occlusion in rats, which is currently believed to best 
mimic the human pathophysiology (Durukan and Tatlisumak, 2007). To precisely identify 
areas of BBB breakdown we made use of fluorescein isothiocyanate (FITC)-labeled albumin 
(FITC-albumin), assumed to represent a non-toxic BBB tracer. To investigate alterations of 
endothelial tight junction complexes in ischemia-affected vessels, we focused on areas 
exhibiting FITC-albumin extravasation by application of electron microscopy to reveal 
ultrastructural details and to provide the route for tracer extravasation. In addition, multiple 
fluorescence labeling was utilized to localize critical tight junction proteins. Noteworthy, 
against our expectation and contradicting the current view on ischemia-induced BBB 
breakdown, we found apparently intact tight junctions in areas of albumin leakage strongly 
suggesting endothelial dysfunction underlying BBB breakdown in stroke.  
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Materials and methods 
Study setup and surgical procedure 
Experiments involving animals were performed according to the European Communities 
Council Directive (86/609/EEC) after protocol approval by local authorities (Landesdirektion 
Leipzig, Germany, reference numbers TVV 02/09 and 34/11). Generally, efforts were made to 
minimize the total number of animals and suffering of animals, which were housed in a 
temperature and humidity controlled room with 12 hours of light/dark cycle and free access to 
food and water. 
Overall 9 male Wistar rats weighing 315 ± 37 g, bred by Charles River (Sulzfeld, 
Germany), were subjected to right-sided embolic middle cerebral artery occlusion (eMCAO) 
as originally described by Zhang et al. (1997) with some minor modifications. Briefly, after 
surgical exposure of right-sided cervical arteries, a polyethylene tubing with tapered end and a 
maximum outside diameter of 0.4 mm was introduced into the external carotid artery and 
moved forward through the internal carotid artery up to the origin of the middle cerebral 
artery (about 1.6 cm from carotid bifurcation). A blood clot (length: 5 ± 0.5 cm) – prepared 
from blood collected in a polyethylene tubing at the previous day and allowed to clot on a 
warming pad (37 °C) for 2 hours followed by overnight storage at 4 °C – was injected with 
about 40 µl of saline. After catheter removal and ligation of the external carotid artery stump, 
the wound was closed. Polyethylene tubes were further inserted into the femoral vein to allow 
future administration of FITC-albumin and femoral artery to control vital parameters during 
surgery. Generally, the surgical procedure was done in anesthesia using 2.0 to 2.5 % 
isoflurane (Isofluran Baxter, Baxter, Unterschleißheim, Germany; mixture: 70 % N2O / 30 % 
O2; vaporisator: VIP 3000, Matrix, New York, USA). To avoid anesthesia-related cooling, the 
body temperature was adjusted to 37.0 °C by a thermostatically controlled warming pad with 
rectal probe (Fine Science Tools, Heidelberg, Germany). Post-surgical pain control was 
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ensured by metamizol- or paracetamol-enriched (Novaminsulfon-ratiopharm, Paracetamol-
ratiopharm, ratiopharm, Ulm, Germany) drinking water.  
 Twenty-four hours after ischemia onset FITC-albumin (20 mg/1 ml saline; Sigma, 
Taufkirchen, Germany) was intravenously administered to allow fluorescence-based 
localization of BBB breakdown, indicated by FITC-albumin leakage (Michalski et al., 2010). 
After a circulation period of usually 1 hour, animals were deeply anesthetized using CO2 and 
transcardially perfused with either 200 ml saline (n=5; for immunohistological analyses by 
fluorescence microscopy), or 200 ml saline followed by 200 ml of a phosphate-buffered 
fixative containing 4 % paraformaldehyde and 0.5 % glutaraldehyde (n=4; for ultrastructural 
analyses by electron microscopy). After extraction of the brains the samples for fluorescence 
microscopy were immediately snap frozen in isopentane on dry ice. 
Fluorescence microscopy and quantification of tight junction integrity 
For fluorescence microscopy, the brains were coronally cut in 10 µm sections on a cryotome 
(Leica Microsystems, Wetzlar, Germany). Before starting the staining procedure, the samples 
were post-fixed with Zinc-formalin for 5 minutes at room temperature followed by several 
rinses with 0.1 M phosphate-buffered saline, pH7.4 (PBS). Unspecific binding of the antibody 
was inhibited by a blocking step applying 5 % of normal goat serum (NGS) and 0.3 % of 
Triton X-100 in PBS for 20 min. The primary antibodies mouse anti-occludin (Antibodies-
online, Aachen, Germany; 1:200), rabbit anti-claudin-5 (Abcam, Cambridge,UK; 1:200), 
rabbit anti-laminin (Dako, Hamburg, Germany; 1:200) and guinea pig anti-GFAP (Synaptic 
Systems, Göttingen, Germany; 1:200) were allowed to incubate over night at 4 °C in PBS 
containing 0.5 % NGS. After several washing steps, the sections were reacted with highly 
purified fluorochromated antibodies (Dianova, Hamburg, Germany; diluted in PBS containing 
0.5% NGS) specifically recognizing IgGs from the host species of primary antibodies for 2 
hours. Subsequently, sections were washed several times in PBS and coverslipped with 
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fluorescence mounting medium (Dako, Hamburg, Germany). Omitting the primary antibodies 
in control experiments resulted in the expected absence of staining. The specimens were 
analyzed with an Olympus BX51 fluorescence microscope (Olympus, Hamburg, Germany) 
equipped with a digital camera. 
For quantification of tight junction integrity, the ratio of tight junction-positive vessels 
with respect to the total number of vessels was captured in the area of FITC-albumin leakage, 
as indicator of BBB breakdown, and compared to the corresponding region on the 
contralateral hemisphere. Therefore, we applied double immunofluorescence staining for 
occludin as marker for endothelial tight junctions and pan-laminin as a general marker for 
cerebral vessels (Sixt et al., 2001). To ensure exclusive analysis of ischemia-affected areas on 
the ipsilateral hemisphere depicting BBB breakdown, we focused on regions showing a clear 
FITC-albumin extravasation into the neuropil. Low power (10x objective) magnification was 
used to count the number of occludin-positive vessels in relation to the total number of 
laminin-immunopositive vessels in usually 8 optic fields per animal and hemisphere, resulting 
in an amount of about 600 to 1,000 vessels per hemisphere. After calculating the ratio per 
optic field, a mean of ratios was build per animal and hemisphere. Finally, the global mean of 
the ipsilateral hemisphere was compared to the contralateral hemisphere, originating from n=5 
animals for each.  
Ultrastructural analysis 
For electron microscopy the brains were consecutively cut in 60 µm sections on a vibratome 
(Leica Microsystems, Wetzlar, Germany) in cooled PBS. The immunohistochemical 
conversion of FITC into an electron-dense reaction product was performed according to 
Michalski et al. (2010) as follows. After several washing steps in 0.1 M Tris-buffered saline, 
pH 7.4 (TBS), the sections were blocked with TBS containing 2 % bovine serum albumin 
(TBS-BSA) for 30 min and then incubated with peroxidase-conjugated anti-fluorescein IgG 
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(Dianova, Hamburg, Germany; 1:2000 = 0.5 µg/ml) in TBS-BSA for 2 hours. Next, the tissue 
was rinsed with TBS twice and with the substrate buffer (0.05 M Tris, pH 7.6) followed by 
staining with diaminobenzidine (DAB) as chromogen. 
After several washing steps in PBS the sections were stained with 0.5 % OsO4 in PBS 
for 30 min. After 5 washing steps the sections were dehydrated using 30 %, 50 % and 70 % of 
ethanol. Subsequently, the tissue was incubated with 1 % uranyl acetate in 70 % ethanol for 1 
hour. Following further dehydration using 80 %, 90 %, 96 %, 100 % ethanol and finally 
propylene oxide the sections were incubated in Durcupan (Sigma Aldrich, Steinheim, 
Germany) and embedded between coated microscope slides and cover slips followed by 
polymerization at 56 °C for 48 hours. After microscopical identification of areas exhibiting 
FITC-albumin leakage demarked by DAB staining the cover slips were removed and the 
respective areas were transferred on blocks of resin followed by another step of 
polymerization at 56 °C for 48 hours. Afterwards, the blocks of resin were trimmed down to 
the areas intended for ultrastructural analysis which were relocated on semi-thin sections and 
then ultra-thin sections of 60 nm thickness were prepared on an ultramicrotome (Leica 
Microsystems, Wetzlar, Germany). Finally, sections were transferred on formvar-coated grids 
and stained with lead citrate for 6 min. Ultrastructural analysis was performed using a Zeiss 
EM900 transmission electron microscope and a Zeiss SIGMA electron microscope equipped 
with a STEM detector, respectively (Zeiss NTS, Oberkochen, Germany). 
Statistical analysis 
The obtained data on tight junction integrity were processed with IBM SPSS Statistics 20 
(IBM Corp., New York, USA). Thereby, the Wilcoxon test was utilized to check for statistical 
significance between means of ratios. In addition, results were further stressed by adding the 
Monte Carlo simulation with 10,000 samples and a confidence interval of 99 %. Generally, a 
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P<0.05 was considered as statistical significant. Data are given as mean ± standard deviation 
unless otherwise indicated. 
Results 
Identification and characterization of areas showing BBB breakdown 25 hours after ischemia 
onset 
According to our previous study (Michalski et al., 2010), the applied model of eMCAO 
resulted in alterations of the vascular architecture with a clear extravasation of FITC-albumin 
in respective areas, primarily located in the right striatum. In contrast, BBB breakdown was 
not observed on the contralateral hemisphere as the respective areas here were devoid of 
FITC-albumin leakage. To distinguish leakage of the tracer into the vascular wall or adjacent 
perivascular spaces from leakage into the neuropil, we applied double fluorescence labeling of 
vascular basement membranes by combined immunostaining for laminin and astroglial GFAP 
(Fig. 1A).  
For ultrastructural analysis and identification of areas showing FITC-albumin leakage, 
we made use of a peroxidase-coupled anti-fluorescein IgG and DAB, which served as 
permanent and electron dense chromogen. To prove the specificity of this technique on 
glutaraldehyde-treated sections for electron microscopy, control stainings were performed on 
consecutive vibratome sections. The specificity of the staining was proven by restriction of 
the DAB signal to the right striatum affected by eMCAO and the absence of any labeling on 
the contralateral hemisphere (Fig. 1B). To precisely focus further ultrastructural analysis to 
areas exhibiting extravasation of the tracer, respective areas were identified after embedding 
of the tissue into resin. Thereby, the embedding procedure allowed light microscopical 
detection of the respective regions, facilitating the localization of areas with tracer 
extravasation and their corresponding contralateral control areas prior to further preparation 
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(Fig. 1C). This protocol allowed confinement of ultrastructural analysis to regions of BBB 
breakdown and their corresponding control areas. 
Expression of critical tight junction proteins in areas of FITC-albumin extravasation 
To further assess whether belts of tight junctions are altered in areas of FITC-albumin leakage 
critical tight junction constituents were analyzed by double fluorescence labeling. In contrast 
to our own expectations, visualization of the essential transmembrane tight junction 
constituents occludin and claudin-5 revealed presence and regular morphology of both 
antigens in control areas as well as in areas of BBB breakdown (Fig. 2). Presence of 
established and still continuous belts of tight junctions in vessels showing bright signals of 
FITC-albumin in the perivascular and juxtavascular area suggests that extravasation of FITC-
albumin does not necessarily depend on a decomposition of endothelial tight junctions in the 
applied model of eMCAO in rats.  
No difference in the distribution of occludin-positive vessels in areas of FITC-albumin 
leakage compared to control areas 
To investigate the question of whether or not there is a statistical significant difference in the 
expression of critical tight junction proteins between areas of FITC-albumin extravasation and 
respective contralateral regions, double fluorescence labeling was applied by use of an 
antibody for laminin as a pan-vessel marker and the critical transmembrane protein occludin 
to demark tight junction complexes. Using low power (10x objective) magnification 
localization of the tracer beyond the glial basement membrane ensured precise confinement of 
analysis to areas showing distinct FITC-albumin leakage into the brain parenchyma. Here, we 
compared the number of occludin- and laminin-positive vessels in areas of BBB breakdown 
and their corresponding control areas (Fig. 3A). As shown in Fig. 3B, nearly identical ratios 
were found for the ischemia-affected (0.966 ± 0.010) and the contralateral hemisphere (0.963 
72
± 0.003), impressively failing statistical significance (Wilcoxon test, P=0.500; Monte Carlo 
simulation, P=0.630).  
Ultrastructural evidence for vascular leakage in areas of morphologically intact tight 
junctions 
Due to apparent limitations of fluorescence microscopy to elucidate minor changes of tight 
junction complexes, electron microscopy was applied to reveal ultrastructural alterations 
responsible for vascular leakage. Using flat-embedded vibratome sections stained with DAB 
to demark the applied tracer, we were able to precisely identify regions of BBB breakdown 
and their corresponding control areas by initial light microscopy (Fig. 1C). On the 
contralateral hemisphere, ultrastructural analysis elucidated intact belts of tight junctions 
within a smooth endothelial layer showing no ultrastructural alterations. The ensheathing 
basement membrane was found to be continuous and the adjacent neuropil appeared 
unaffected (Fig. 4A). In areas of FITC-albumin extravasation, the juxtavascular parenchyma 
often displayed edema of astrocytic endfeet, in conformity with Ito et al. (2011), and also 
cellular debris. On the abluminal side of the vascular basement membrane DAB grains 
regularly indicated extravasation of the applied tracer. However, in these segments of the 
vascular tree, the tight junctions were still found to be intact, thus sealing the endothelial layer 
as shown by fluorescence microscopy before (Fig. 4B-D). 
Ultrastructural evidence for transcellullar, not paracellular leakage 
As evidence for leakage through altered endothelial tight junctions was lacking, a more 
detailed comparison between the vasculature on the control hemisphere and areas of FITC-
albumin leakage on the ipsilateral hemisphere was performed to search for signs of 
transcellular leakage. In control areas, the endothelium appeared not to be affected by the 
experimental procedure. The nuclei exhibited the typical distribution pattern of euchromatin 
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and heterochromatin, but hardly any transcellular vesicles. Adjacent cells within the 
neurovascular unit appeared normal and extravasation of the tracer was not observed (Fig. 
5A). In contrast, endothelial cells within areas of BBB breakdown often showed a ruffled 
vascular surface with dramatically increased numbers of cytoplasmic vesicles. As described 
above, tight junction complexes concomitantly appeared to be intact (Fig. 5B). Around 
vessels showing the described alterations grains of DAB were regularly observed in adjacent 
perivascular spaces or within the neuropil. Therefore, we propose that the contribution of 
leaky belts of tight junctions to the failure of the endothelial BBB characteristics is rather 
questionable in the model of eMCAO. More likely, it is the result of a failure in suppressing 
vesicle-mediated leakage through the endothelium itself.
Evidence for leakage across disintegrated endothelium 
In addition to the finding of an enhanced vesicle transport through the endothelial layer, a 
disintegration of endothelial cells was often observed allowing direct extravasation of FITC-
albumin into perivascular spaces and the adjacent neuropil. Here, the luminal plasma 
membrane frequently appeared to be discontinuous. Thus, the former barrier for blood-borne 
molecules towards the brain parenchyma proper is often constituted by endothelial debris and 
remnants of the vascular basement membrane only (Fig. 6). 
Discussion 
Despite their enormous clinical relevance, the mechanisms underlying BBB breakdown 
during ischemic stroke are still poorly understood and consequently this research topic 
achieved high priority rating in the field of cerebral ischemia (Meairs et al., 2006). In the past, 
promising concepts of stroke treatment developed by experimental research using different 
animal models have often failed to be transferred into the clinical setting, such as in the case 
of NXY-059 (Diener et al., 2008; Fisher et al., 2009). Since the ways to reproducibly mimic 
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conditions of cerebal ischemia in experimental models are limited, investigators are often 
forced to make use of artificial and unphysiological ways to decrease blood flow in respective 
cerebral vessels (Young et al., 2007). Thus, frequently used techniques vary from 
electrocoagulation or ligation to the internal occlusion of the vascular lumen by inserted 
filaments (Bräuninger and Kleinschnitz, 2009). Furthermore, the applied tracers to investigate 
a putative leakage of the endothelial barrier such as dextrans (Nagaraja et al., 2008; Chen et 
al. 2009) or the widely utilized Evans blue (Qin et al., 2007; Yang et al., 2007; Liu et al., 
2008; Wang et al., 2009; Zhao et al., 2010) may also provide toxic or immunological side 
effects, thereby disturbing the physiological environment of the NVU and its constituents. 
Moreover, investigation of cellular mechanisms and intracellular signaling cascades 
predominantly requires use of in vitro experiments, which are useful to study endothelial 
function, but not pathophysiological events of the complete NVU including pericytes, 
astrocytes, neurons and components of the extracellular matrix, which act in concert to 
maintain the barrier function of the cerebral vasculature (Bechmann et al., 2007; Zlokovic, 
2008, del Zoppo, 2010; Engelhardt, 2011; Osada et al., 2011).  
In order to minimize artificial alterations, we used an embolic model of ischemic 
stroke in rats, which is believed to best mimic the human pathophysiology (Durukan and 
Tatlisumak, 2007). Furthermore, BBB leakage was assessed by injected FITC-labeled 
albumin which is reported to display the same pattern of extravasation as traditionally used 
tracers such as rat IgG (Michalski et al., 2010). The use of the established tracer FITC-
albumin thereby enabled a clear-cut identification of areas affected by BBB breakdown and 
the application of double fluorescence labeling for transmembrane tight junction constituents 
allowed simultaneous analyses of endothelial belts of tight junctions.  
Although alterations of tight junctions have been described in several models of 
hypoxia and stroke before (McCaffrey et al., 2009; Bauer et al., 2010; Jiao et al., 2011; Liu et 
al., 2012; Yu et al., 2012), we were not able to correlate areas of FITC-albumin leakage with 
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alterations in the expression pattern of the transmembrane proteins occludin and claudin-5 in 
this model of focal cerebral ischemia (Fig. 2). This finding was confirmed by a quantitative 
analysis based on the presence of essential tight junction proteins in areas of FITC-albumin 
extravasation compared to control regions on the contralateral hemisphere. In detail, 
immunolabeling of the transmembrane protein occludin demarked endothelial belts of tight 
junctions and laminin-immunoreactivity served as a vascular basement membrane marker 
(Sixt et al., 2001), allowing a ratio of occludin-positive vessels to be calculated. Importantly, 
these ratios did not differ when comparing areas of FITC-albumin leakage and the respective 
control regions (Fig. 3), indicating not only a lack of qualitative but also of quantitative 
changes.  
To rule out that possible alterations of the endothelial tight junctions remain 
undetected due to limitations of fluorescence microscopy, electron microscopy was applied to 
analyze ultrastructural changes within the endothelial layer. As previously described 
(Michalski et al., 2010), we used the nearly background-free immunohistochemical 
conversion of FITC-albumin by peroxidase-coupled anti-fluorescein into the electron-dense 
chromogen DAB to specifically identify areas of BBB breakdown. In fact, by embedding of 
DAB stained vibratome sections under coated cover glasses, we were able to identify 
respective areas and the exact location on the contralateral hemisphere before preparation of 
ultra-thin sections for electron microscopy. Conversion of FITC-albumin into DAB 
ultrastructurally resulted in a typical granular staining, which was strictly confined to sites of 
extravasation of the tracer. In line with our findings based on fluorescence microscopy, at 25 
hours after ischemia onset the tight junction complexes were regularly found to be established 
although DAB grains clearly indicated extravasation into perivascular spaces or the adjacent 
neuropil (Fig. 3). These results are clearly contrary to several recent studies describing 
ultrastructural alterations of tight junctions in diverse models of hypoxia and stroke 
(Matsuzaki et al., 2010; Jiao et al., 2011). However, the traditional link between presence of 
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tight junctions and BBB integrity as well as the variety of valuable data demonstrating altered 
expression patterns of tight junction proteins in models of hypoxia and stroke (Fischer et al., 
2000; Mark and Davis, 2002; McCaffrey et al., 2009; Bauer et al., 2010; Jiao et al., 2011; Yu 
et al., 2012) may have constituted a bias affecting interpretation of ultrastructural images. 
Thus, questionable alterations were addressed as intercellular openings or tight junction loss 
(Matsuzaki et al., 2010; Jiao et al., 2011). 
However, Reese and Karnovsky (1967) who first described endothelial tight junctions 
as ‘morphological correlate of a BBB’ also considered in the same paper ‘paucity of 
transcytotic vesicles’ as a mechanism to prevent penetration of hydrophilic molecules into the 
brain (Reese and Karnovsky, 1967). It is interesting to note that an early study investigating 
the effect of hypertension after cerebral ischemia already suggested an upregulation of the 
transcellular vesicle transport to result in a transendothelial leakage pattern (Ito et al., 1980). 
However, this concept was widely neglected by later investigators. 
As we were also not able to demonstrate loss of tight junctions, we further analyzed 
the areas of tracer extravasation for differences in the distribution of transcytotic and 
pinocytotic vesicles compared to respective control areas. Indeed, we found a remarkable 
increase of these vesicles in areas of FITC-albumin leakage while control areas exhibited no 
or scarcely any vesicles at all (Fig. 5). Furthermore and supporting the hypothesis that the 
contribution of an interendothelial opening by a displacement of endothelial tight junctions 
may be overestimated, we frequently observed a distintegration of the endothelial layer itself, 
thereby allowing unhindered extravasation of blood-borne molecules (Fig. 6). Given that the 
alterations revealed in this study were that striking, it is reasonable to assume that they should 
be primarily responsible for the observed BBB breakdown after ischemic stroke. Therefore, 
we suggest that it is not a downregulation of tight junction proteins to cause extravasation of 
blood-derived substances in the manner of an interendothelial leakage, but more likely an 
endothelial dysfunction leading to extravasation of blood-derived molecules over the whole 
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surface of affected endothelial cells, which may be related to an upregulation of caveolin-1 
under hypoxic conditions (Wang et al., 2012). Thus, effects on the expression of tight 
junction constituents do not necessarily represent the cause for BBB breakdown but may 
rather be a consequence of a dysfunctioned endothelial layer which allows transcellular 
leakage. Although our data need to be complemented by a temporal perspective in future 
studies since BBB alterations were described to occur in a time-dependent manner (Belayev et 
al., 1996; Strbian et al., 2008), the present findings may contribute to a better understanding 
of the NVU under ischemic conditions. Furthermore, the obtained results, showing 
predominantly dysfunctional endothelial cells, may pave the way towards novel 
neuroprotective strategies. 
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Figure legends 
Figure 1 (A) Double fluorescence labeling of laminin (color-coded in blue) and GFAP (red) 
in combination with applied FITC-albumin (green) reveals areas of ischemia-related BBB 
breakdown. By application of both, an antibody detecting astrocytes (GFAP, red) and an 
antibody for pan-laminin (blue) which visualizes vascular as well as glial basement 
membranes (Sixt et al., 2001) the observed leakage can clearly be demonstrated to reach the 
brain parenchyma proper. Therefore, FITC-albumin is detectable within all the three 
compartments of the neurovascular unit, represented by the vascular wall (1st compartment), 
the perivascular space (2nd compartment) and the adjacent neuropil (3rd compartment), 
delineated by astocytic endfeet (red) forming the glia limitans (Bechmann et al., 2007). (B) 
To prove specificity of the applied reagent used for conversion of extravasated FITC-albumin 
into a permanent labeling by DAB for ultrastructural analysis, we exemplarily performed 
control stainings on vibratome sections, which were not further processed for electron 
microscopy. The low magnification of a coronary section clearly demonstrates the specificity 
of the applied reagent and its reaction product (DAB, brown). These sections were 
counterstained with hemalaun (blue). Areas of FITC-albumin leakage are clearly confined to 
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the striatum. Higher magnification reveals a general leakage of FITC-albumin into the 
neuropil (brown background). In perivascular and juxtavascular areas the DAB staining 
appears to be more intense. (C) To confine ultrastructural analysis to areas with BBB 
breakdown, we identified areas of FITC-albumin extravasation after embedding in resin on 
coated microscope slides. These areas were selectively processed for ultrastructural analysis 
by electron microscopy. In corresponding control areas no FITC-albumin extravasation was 
observed. Please note, the general brown tissue background is a consequence of the 
embedding procedure using OsO4 and uranyl acetate, which clearly can be distinguished from 
DAB staining as indicated on the left. 
Figure 2 Double fluorescence labeling of claudin-5 (blue) and occludin (red), both being 
transmembrane proteins critical for tight junction formation, demonstrates extravasation of 
FITC-albumin (green) in the vicinity of vessels expressing both markers. Please also note the 
presence of discontinuities in the staining pattern of control vessels with an ‘intact’ 
endothelial barrier (arrow heads). 
Figure 3 (A) Quantitative analysis of differences in the expression of occludin in areas of 
FITC-albumin extravasation and their corresponding control areas was performed using low 
power (10x objective) magnification. Here, laminin-immunolabeling revealed the total 
number of vessels, whereas occludin-immunoreactivity visualized a critical tight junction 
constituent. The ratio of occludin-positive vessels to the total number of vessels was 
determined in 5 animals. (B) The ratio of occludin-positive vessels to the total number of 
vessels did not differ significantly in areas of FITC-albumin leakage and their corresponding 
control areas. Bars represent means and added lines represent standard errors. 
Figure 4 (A) Ultrastructural analysis of a control area located on the contralateral hemisphere 
shows a smooth endothelial layer (E) with an intact tight junction complex (arrow). The 
surrounding basement membrane is clearly visible and the adjacent neuropil does not show 
any structural alterations. (B-D) In areas of FITC-albumin extravasation the tight junction 
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complexes (arrows) regularly appear to be established. The adjacent neuropil often displays 
cellular edema and cellular debris. Extravasated FITC-albumin and its product of conversion 
(black DAB grains, arrow heads) can constantly be found in the adjacent brain parenchyma 
proper. E = endothelial cells; L = vascular lumen 
Figure 5 (A) Vessels in control areas on the contralateral hemisphere do not show signs of a 
transcellular, vesicle-mediated extravasation of FITC-albumin. (B-D) In contrast to alterations 
within the belts of tight junctions, ultrastructural examination regularly revealed signs for a 
transcellular leakage of the tracer. The endothelial cytoplasm exhibits a remarkable increase 
in vesicle density (white arrows) across the whole vascular circumference. Again, tight 
junctions (black arrow) are found to be intact. DAB grains are indicated by arrow heads. 
Control = contralateral hemisphere, E = endothelial cells; L = vascular lumen 
Figure 6 In addition to the observation of a dramatic increase of the vesicle density, we often 
observed a disintegration of the whole endothelial layer. In areas exhibiting BBB breakdown 
the cellular surface of the endothelium was frequently found to be ruffled or discontinuous. 
Therefore, the vascular wall was often shown to consist of endothelial debris and basement 
membranes, only (brackets). Thus, in contradiction to a variety of studies our data strongly 
suggest a transendothelial leakage pattern of affected vessels. DAB grains indicating 
extravasation of FITC-albumin are demarked by arrow heads. 
E= endothelial cells; L= vascular lumen; asterisk= cellular debris in the lumen of the vessel; 
arrow heads= DAB grains; arrow= tight junction 
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Zur lebensnotwendigen Aufrechterhaltung der neuronalen Aktivität innerhalb des 
Zentralnervensystems bedarf es einer strengen Regulierung des einzigartigen 
neuronalen Milieus. Dies wird gewährleistet, indem eine Vielzahl an Mechanismen die 
Zufuhr von Nährstoffen und Sauerstoff in das Zentralnervensystem sicherstellen und 
gleichzeitig den Übertritt potentiell toxischer Substanzen aus dem Blut in das 
Hirnparenchym verhindern. Ebenso wichtig für die Aufrechterhaltung der Funktionen des 
Gehirns ist aber auch die strikte Kontrolle von Entzündungsreaktionen im Falle von 
Infektionen durch das Immunsystem. Allumfassend wurde dieses Prinzip bislang nur 
unzureichend mit dem Konzept der Bluthirnschranke erklärt. Dieser geht ursprünglich 
auf die Eigenschaft zerebraler Gefäße zurück, bestimmte, im Blut gelöste Substanzen in 
den Gefäßen zurückzuhalten, während Blutgefäße peripherer Organe den Austritt in das 
umliegende Gewebe größtenteils ermöglichen. Diese Eigenschaft wird, wie anfangs 
angenommen, aber nicht allein von den Endothelzellen der hirneigenen Gefäße 
bestimmt, sondern ist vielmehr dem vielstimmigen Zusammenspiel einer Vielzahl an 
Zellpopulationen und Komponenten der extrazellulären Matrix geschuldet, die man auch 
unter dem Begriff der neurovaskulären Einheit zusammenfasst.  
Aufgrund der Beobachtung, dass Immunreaktionen im Zentralnervensystem einer 
strengen Kontrolle unterliegen und der einfachen Tatsache, dass Leukozyten im Gehirn 
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viel weniger zahlreich wie in anderen Organen vorkommen, wurde der Begriff der 
Bluthirnschranke missverständlicherweise ebenfalls in den Kontext der 
Neuroimmunologie übertragen. In diesem Zusammenhang sind verschiedene Dogmen 
erwähnenswert, die eine immunologische Sonderstellung des Gehirns als so genanntes 
Immunprivileg begründen. Hierbei handelt es sich um die Annahmen, dass es im 
gesunden Gehirn keine antigenpräsentierenden Zellen gibt, ein fehlender Lymphabfluss 
den Abtransport von Antigenen aus dem Zentralnervensystem verhindert und die 
Bluthirnschranke den Eintritt von Immunzellen in das Gehirn unterbindet. 
Wir beschäftigten uns daher mit der Frage, ob im Gehirn eine Population CD11c-
positiver Zellen existiert, die als antigenpräsentierende Zellen fungieren könnte. Dabei 
verwendeten wir einen transgenen Mausstamm, der ein grün fluoreszierendes Protein 
(GFP) zur Markierung CD11c-postiver Zellen unter dem CD11c Promotor itgax 
exprimiert, da kommerziell erhältliche Antikörper gegen diese Zellpopulation im 
Mausmodell nur unzureichende Ergebnisse lieferten. Hierbei konnten wir nachweisen, 
dass CD11c-positive Zellen in der Abwesenheit von Pathologien im Gehirn vorkommen 
und diese darüber hinaus fast ausschließlich in Hirnabschnitten lokalisiert sind, die mit 
Prädilektionsstellen der Multiplen Sklerose, einer häufigen Autoimmunerkrankung, 
korrelieren. Darüber hinaus stellte sich uns die Frage, in welchen Kompartimenten diese 
Zellen genau lokalisiert sind, da Publikationen der letzten Jahre diese Zellen im 
perivaskulären Raum, das heißt außerhalb des eigentlichen Hirnparenchyms, 
vermuteten. Mit Hilfe der Elektronenmikroskopie und Semidünnschnitten konnten wir 
nach Konvertierung des GFP in ein licht- und elektronendichtes Präzipitat mittels DAB-
Reaktion die genaue Lokalisierung dieser Zellen im Hirnparenchym nachweisen. 
Darüber hinaus waren wir in der Lage zu zeigen, dass diese Zellen einen Teil der Glia 
limitans bilden und daher mit ihren Fortsätzen direkten Kontakt zur glialen 
Basalmembran haben. Dies ist immunologisch von großem Interesse, da diese 
Zellpopulation in einer strategisch wichtigen Position existiert, um im Rahmen der 
Neuroinflammation Antigene an Zellen innerhalb der perivaskulären Räume zu 
präsentieren. Weiterhin konnten wir in dieser Studie mit Antikörperfärbungen an 
humanen Hirnschnitten zeigen, dass ebenfalls beim Menschen eine Zellpopulation 
vorkommt, die mit der von uns im Mausmodell gefundenen Art in Bezug auf deren 
Lokalisation übereinstimmt. 
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 Obwohl in der letzten Zeit durch mehrere Studien der Abtransport von Antigenen aus 
dem Gehirn in zervikale Lymphknoten diskutiert wird, konnte der direkte Nachweis einer 
zellulären Emigration nicht immer erbracht werden. Insbesondere über die Route des 
Abflusses herrscht weiterhin Unklarheit, wobei zwei Varianten besonderes Interesse 
verdienen. So konnten einige Studien aus unserer Arbeitsgruppe zeigen, dass 
zumindest ein zellvermittelter Transport von Antigenen über die Lamina cribrosa in die 
nasale Mukosa und damit zu den zervikalen Lymphknoten denkbar ist. Zum anderen 
geht eine andere Theorie davon aus, dass gelöste Stoffe über die 
Zerebrospinalflüssigkeit entlang der arteriellen Basalmembranen einen Anschluss an 
zervikale Lymphgefäße finden.  
Da dieser Transport und damit die mögliche Antigenpräsentation von Antigenen aus 
dem Gehirn im Rahmen der Entstehung von Autoimmunerkrankungen wie der Multiplen 
Sklerose diskutiert werden, haben wir untersucht, ob massives Freisetzen von 
oligodendrozytenspezifischen Antigenen im Gehirn eine entsprechende Autoimmunität 
auslösen kann. Hierfür verwendeten wir im Tiermodell einen transgenen Mausstamm, 
der spezifisch in Oligodendrozyten die Expression eines Diphterietoxinrezeptors 
induziert, wodurch nach Gabe des Toxins spezifisch Oligodendrozyten im Gehirn getötet 
werden können, was große Mengen an myelinspezifischen Antigenen frei werden lässt. 
Diesen Myelinschaden konnten wir elektronenmikroskopisch nachweisen und das 
Absterben der Oligodendrozyten dokumentieren. Hierbei wurden myelinspezifische 
Antigene frei, die durch Proteinnachweismethoden in zervikalen Lymphknoten 
nachgewiesen werden konnten. Obwohl damit T-Zellen Zugang zu diesen Antigenen 
hatten, konnte in diesem Modell jedoch keine Autoimmunität gegen Antigene im Gehirn 
nachgewiesen werden. Da insbesondere für die Multiple Sklerose eine Genese durch 
einen primären Oligodendrozytenschaden diskutiert wurde, ist dieser Befund klinisch 
höchst relevant.  
 
Da die Metapher der Bluthirnschranke historisch und experimentell eng mit der Intaktheit 
endothelialer Tight junctions verknüpft ist, wird deren Bedeutung auch beim 
ischämischen Schlaganfall und der assoziierten Schrankenstörung durch eine Vielzahl 
an Studien herausgehoben. In der Tat konnte in Tiermodellen der fokalen oder globalen 
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Ischämie aber auch in-vitro eine verminderte Expression von essentiellen Proteinen der 
Tight junctions nachgewiesen werden, die mit einer Schrankenstörung gegenüber 
gelösten Stoffen assoziiert ist. Obwohl jedoch ebenfalls eine Endothelschädigung in 
anderen Modellen als Ursache einer Bluthirnschrankenstörung diskutiert wurde, die 
einen transendothelialen Prozess, nicht aber einen parazellulären favorisierte, fand 
diese Theorie keine Akzeptanz. Da bislang der ultrastrukturelle Nachweis einer Öffnung 
endothelialer Tight junctions als Ursache einer Bluthirnschrankenöffnung fehlt, 
versuchten wir mit Hilfe von fluoreszenz- und elektronenmikroskopischen Methoden 
diesen Nachweis im Tiermodell des embolischen Schlaganfalls zu erbringen. Hierfür 
verwendeten wir FITC-konjugiertes Albumin als Permeabilitätsmarker, das sowohl 
fluoreszenzmikroskopisch und nach DAB-Konvertierung auch elektronenoptisch 
nachweisbar ist. Entgegen unseren Erwartungen fanden wir in Gebieten mit deutlichem 
FITC-Albumin Austritt jedoch die Immunreaktivität gegenüber relevanten Tight junction 
Markern erhalten und konnten mit Hilfe der Fluoreszenzmikroskopie nicht nur qualitativ, 
sondern auch quantitativ gegenüber der Kontrollregionen keine Unterschiede feststellen. 
Um auszuschließen, dass die Fluoreszenzmikroskopie nicht sensitiv genug ist, um diese 
Veränderungen nachzuweisen, die zur verstärkten Gefäßpermeabilität gegenüber 
Albumin führt, untersuchten wir entsprechende Areale ebenfalls 
elektronenmikroskopisch. Auch hier bestätigte sich die regelhafte Intaktheit der 
gürtelförmigen Verschlusskontakte. Hingegen wiesen die Endothelzellen eine 
dramatische Vermehrung transzytotischer Vesikel auf, welche für die 
Bluthirnschrankenstörung verantwortlich sein könnte. Neben diesem Befund konnten wir 
weiterhin die Auflösung ganzer Endothelzellen als Austrittsweg aus dem Gefäß in das 
Hirnparenchym nachweisen. Aus diesem Grund hinterfragen wir die etablierte Ansicht, 
dass eine Bluthirnschrankenstörung mit einer Zerstörung endothelialer Tight junctions im 
Sinne eines parazellulären Lecks einhergeht. Wir konnten erstmals 
elektronenmikroskopisch in einem der menschlichen Pathophysiologie ähnlichen Modell 
zeigen, dass der verstärkten Gefäßpermeabilität nach fokaler, zerebraler Ischämie ein 
transendothelialer Mechanismus aufgrund eines assoziierten Endothelschadens 
zugrunde liegt. 
Diese Ergebnisse tragen somit zu einem besseren Verständnis der Funktion der 
neurovaskulären Einheit im Gesunden als auch unter pathologischen Veränderungen 
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bei. Die Berücksichtigung des Zusammenspiels aller beteiligten Zellpopulationen wird 
somit hoffentlich zur Etablierung neuer Modelle beitragen, die es ermöglichen, Befunde 
aus vorklinischen Studien in Therapiekonzepte für den klinischen Alltag zu übertragen. 
 
6. Summary 
It is vitally important to maintain proper neuronal activity within the central nervous 
system (CNS), a need which requires a stringent maintenance and regulation of the 
unique neuronal milieu. This process involves a variety of mechanisms maintaining the 
supply of nutrients and oxygen within the CNS and in parallel restricting entrance of 
potentially toxic substances from the blood into the CNS parenchyma. To keep up 
proper functioning of the brain it is also important to tightly control immunoreactivity in 
cases of infectious diseases. These mechanisms are often imprecisely and misleadingly 
explained by the metaphor of the blood-brain barrier (BBB). This notion originally relates 
to the ability of cerebral vessels to hold back certain hydrophilic molecules from entering 
the brain, while vessels of peripheral organs regularly allow extravasation into adjacent 
tissues. But this phenomenon is not defined by the endothelial layer alone, it is rather a 
result of several populations of cells and components of the extracellular matrix acting in 
concert to maintain BBB properties of cerebral vessels, which are commonly described 
as the neurovascular unit (NVU). 
Misleadingly, the concept of the BBB was taken over by neuroimmunologists as it 
seemed to perfectly explain the old observation that leukocytes are rare in the brain and 
that immunological processes are strictly regulated in the CNS. In this context it is worth 
mentioning some dogma which try to explain the outstanding features of the CNS which 
are subsumed under the concept of an immune privilege. This is commonly believed to 
be established by the absence of cells within brain capable of antigen presentation, by 
the absence of an afferent arm of the lymphatic system as the CNS is lacking lymphatic 
vessels and finally by the BBB inhibiting entrance of leukocytes into the brain 
parenchyma. 
We therefore wanted to investigate the question of whether or not there are CD11c-
postive cells, which may act as antigen presenting cells. Using a transgenic mouse 
strain expressing a green fluorescent protein (GFP) under the CD11c promoter itgax, we 
were able to trace CD11c-positive cells as available antibodies only provided 
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questionable results. Thus, we were able to detect CD11c-postive cells, which were not 
regularly distributed throughout the brain but confined to predilection areas of Multiple 
sclerosis. Furthermore we investigated the question in which compartment of the 
neurovascular unit these cells indeed reside as there are studies suggesting them to be 
localized within perivascular spaces. Applying electron microscopy and light microscopy 
using semi-thin sections of DAB stained tissue we were able to localize this population 
inside the brain parenchyma. Moreover, we were able to demonstrate their participation 
in forming the glia limitans as CD11c-positive cells had direct contact to the glial 
basement membrane. Thus, they are ideally positioned to potentially present antigen to 
cells within perivascular spaces. Finally, applying anti-CD209 staining on human brain 
slices we demonstrated the existence of a similar population in humans. 
Although several studies recently discussed drainage of CNS antigens to cervical lymph 
nodes, the authors often failed in distinguishing cellular transportation from passive 
drainage. Particularly the exact route of this potential mechanism is still matter of debate 
as at least two major theories exist. At least a transport mediated by cells traversing the 
lamina cribrosa towards the nasal mukosa has been discussed as our group was 
recently able to demonstrate this route for leukocytes toward cervical lymph nodes. 
Another concept of antigen drainage includes the basement membranes of arterial 
vessels, which gain access to lymph vessels outside of the skull. 
This transport of CNS-derived antigens to cervical lymph nodes has repeatedly been 
discussed to drive autoimmune diseases such as multiple sclerosis. Therefore, we 
investigated whether or not massive release of myelin-associated antigens may trigger 
autoimmune reactions in the brain. Thus, we applied an animal model using trangenic 
mice exclusively expressing the diphtheria toxin receptor on oligodendrocytes thereby 
allowing an inducible depletion of oligodendrocytes within the CNS which leads to a 
robust release of myelin-related antigens. Using electron microscopy, we were able to 
demonstrate consecutive demyelination and degeneration of affected oligodendrocytes 
in this model. Hence, myelin-associated antigens were detectable in cervical lymph 
nodes thereby proving antigen drainage from the brain. Although T-cells thus had 
access to myelin in the cervical lymph nodes, we were not able to demonstrate 
autoimmunity against brain-derived antigens. As a primary damage to oligodendrocytes 
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was discussed to participate in the pathogenesis of Multiple sclerosis, these results are 
strikingly relevant in the field of neuroimmunology. 
The metaphor of the BBB is historically linked to the intact belts of tight junctions, 
described by Reese and Karnovsky in 1967. Therefore, their contribution to blood-brain 
barrier breakdown associated with ischemic stroke was repeatedly discussed. Indeed, 
using in-vitro and animal models of global and focal ischemia several studies 
demonstrated alterations of critical tight junction proteins, which were associated with an 
increased permeability of the applied tracers. Though, in another models a different 
mechanism of BBB breakdown was suggested which favoured an endothelial damage 
allowing transcellular, not paracellular leakage into the brain parenchyma. However, this 
concept was rather neglected, although ultrastructural evidence for an interendothelial 
opening by a disassembly of endothelial tight junctions is still lacking. Therefore, we 
applied fluorescence based and electron microscopy to investigate this issue in an 
embolic model ischemic stroke in rats. Using FITC-labelled albumin we investigated the 
fate of tight junctions in areas of tracer extravasation. Against our expectation, stainings 
for critical tight junction proteins demonstrated intact belts of tight junctions in areas of 
BBB breakdown. Furthermore, quantification revealed lack of quantitative changes 
observed by fluorescence microscopy between affect regions and control areas. To rule 
out that fluorescence microscopy is not sensitive enough to demark minor changes, we 
applied electron microscopy for further ultrastructural analysis. Substantiating our 
previous findings, tight junction complexes regularly remained intact in areas of tracer 
extravasation. Furthermore, a dramatic increase of transendothelial vesicles were 
observed probably being responsible for BBB breakdown. Often, the whole endothelial 
layer was found to be disintegrated, thus allowing unhampered extravasation of blood-
borne molecules into adjacent compartments. Therefore, we challenge the established 
view on the critical impact of tight junction complexes to contribute to a paracellular 
leakage pattern. In contrast, we provide novel evidence for a transcellular leakage 
across damaged endothelial cells in an animal model of focal cerebral ischemia which is 
described to be the closest to the human pathophysiology. 
These data will therefore hopefully contribute to a better understanding of the NVU 
under physiological and pathological conditions. Consideration of the dynamic 
interaction of the different populations contributing to the maintenance of neuronal 
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function might allow the development of new concepts and their consecutive translation 
into clinical routine. 
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